

Edgar Filing: RESPIRONICS INC - Form 10-K

RESPIRONICS INC
Form 10-K
September 30, 2002

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 10-K

(Mark One)

X Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended June 30, 2002 or

Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from _____ to _____

Commission File No. 000-16723
RESPIRONICS, INC.

(Exact name of registrant as specified in its charter)

Delaware 25-1304989
(State or other jurisdiction of (I.R.S. Employer Identification Number) incorporation or organization)

1010 Murry Ridge Lane
Murrysville, Pennsylvania 15668-8525
(Address of principal executive offices) (Zip Code)

(Registrant's Telephone Number, including area code) 724-387-5200

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Name of each exchange on which registered
----- None	----- --

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, par value \$.01 per share
(Title of Class)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods that the registrant was required to file such reports) and (2) has been subject to such filing requirements for at least the past 90 days. Yes X No .

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. []

As of August 31, 2002, the aggregate market value of the shares of the registrant's Common Stock (based upon the last price reported by the NASDAQ National Market System) held by non-affiliates was approximately \$1,105,000,000.

As of August 31, 2002, there were 36,956,077 shares of Common Stock of the registrant outstanding, of which 3,592,654 were held in treasury.

Edgar Filing: RESPIRONICS INC - Form 10-K

Documents incorporated by reference: Portions of the Proxy Statement for the registrant's Annual Meeting of Shareholders to be held on November 18, 2002 are incorporated by reference into Part III of this Annual Report on Form 10-K.

INDEX

	Page

PART I	
Item 1. Business	3
Item 2. Properties	15
Item 3. Legal Proceedings	15
Item 4. Submission of Matters to a Vote of Security Holders	16
PART II	
Item 5. Market for Registrant's Common Equity and Related Shareholder Matters	16
Item 6. Selected Financial Data	17
Item 7. Management's Discussion and Analysis of Results of Operations and Financial Condition	19
Item 7A. Quantitative and Qualitative Disclosures About Market Risk	23
Item 8. Consolidated Financial Statements	26
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	48
PART III	
Item 10. Directors and Executive Officers of the Registrant	49
Item 11. Executive Compensation	49
Item 12. Security Ownership of Certain Beneficial Owners and Management	49
Item 13. Certain Relationships and Related Transactions	49
PART IV	
Item 14. Controls and Procedures	50
Item 15. Exhibits, Financial Statement Schedules and Reports on Form 8-K	50
Signatures	52

PART I

CAUTIONARY STATEMENT FOR PURPOSES OF THE "SAFE HARBOR" PROVISIONS OF THE PRIVATE SECURITIES REFORM ACT OF 1995.

Edgar Filing: RESPIRONICS INC - Form 10-K

The statements contained in this Annual Report on Form 10-K, including those contained in Item 1 "Business" and Item 7 "Management's Discussion and Analysis of Results of Operations and Financial Condition," and statements incorporated by reference in this Form 10-K from the 2002 Annual Report to Shareholders, along with statements in other reports filed with the Securities and Exchange Commission, external documents and oral presentations which are not historical are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21B of the Securities Exchange Act of 1934, as amended. These forward-looking statements represent the Company's present expectations or beliefs concerning future events. The Company cautions that such statements are qualified by important factors that could cause actual results to differ materially from the expected results included in the forward-looking statements. Those factors include, but are not limited to, the following: foreign currency fluctuations, regulations and other factors affecting operations and sales outside the United States including potential future effects of the change in sovereignty of Hong Kong, customer consolidation and concentration, increasing price competition and other competitive factors in the sale of products, the success of the Company's marketing, sales, and promotion programs, interest rate fluctuations, intellectual property and related litigation, other litigation, successful integration of acquisitions, FDA and other government regulation, anticipated levels of earnings and revenues, and third party reimbursement.

Item 1. Business -----

Note: This document contains a variety of technical terms pertaining to the Company's business, which are explained below:

Continuous positive airway pressure or "CPAP" - continuous air pressure into a patient's airway provided by an air pressurization device

Bi-level positive airway pressure or "BiPAP" - air pressure provided to a patient's airway by an air pressurization device under which the pressure increases and decreases based on the patient's breathing pattern

Bi-level non-invasive ventilatory support - bi-level positive airway pressure provided into the patient's airway via a mask to supplement, but not replace, the patient's own breathing

Invasive volume ventilators - a ventilator that delivers a mixture of air and oxygen into a patient's lungs via a tube inserted into the patient's airway; these patients are dependent on the ventilator for life support

Non-invasive monitors - devices that provide measurements of a patient's physiological data via sensors that are affixed outside the patient's body (i.e. a small clip that fits over a patient's fingertip)

Leak sensing technology - a feature of the Company's bi-level non-invasive units whereby the units sense that an air leak has occurred between the mask and the patient's face and the unit adjusts its air flow to compensate for the leak

Molecular sieve - material used in oxygen concentrators for separating oxygen from room air.

Tracheal gas insufflation - a means of reducing elevated levels of carbon dioxide in patients being treated with ventilators

Edgar Filing: RESPIRONICS INC - Form 10-K

General

Respironics, Inc. is a leading developer, manufacturer and marketer of medical devices used primarily for the treatment of patients suffering from respiratory disorders. The Company's products are designed to reduce costs while improving the effectiveness of patient care and are used primarily in the home and in hospitals along with alternative care facilities and in emergency medical settings. The Company's primary product lines are: (i) homecare products, including continuous positive airway pressure ("CPAP") devices and bi-level positive airway pressure devices used in the home for the treatment of obstructive sleep apnea ("OSA"), a serious disorder characterized by the repeated cessation of breathing during sleep, respiratory devices including bi-level non-invasive ventilatory support units, portable invasive volume ventilator units used in the home, home oxygen devices, diagnostic and monitoring systems, and developmental care products used for premature infants; (ii) hospital products, including bi-level non-invasive ventilatory support units, critical care units that can deliver both non-invasive and invasive ventilation, noninvasive cardiorespiratory monitors, sensors, and related disposable accessories, all of which are used in hospital or institutional settings; and (iii) asthma and allergy products. Respironics markets its products through homecare, hospital, asthma and allergy, and international sales organizations, which consist of approximately 370 direct and independent sales representatives and sales management personnel who sell to a network of over 5,000 medical product service providers and dealers (commonly referred to as "dealers") and, in some cases, directly to hospitals and other institutions. The Company also rents certain of its products to dealers and, in limited cases, directly to end users. With over 80% of its sales currently reaching the home care market, Respironics believes that it is well positioned to take advantage of the growing preference for in-home treatment of patients suffering from respiratory disorders.

Respironics is a Delaware corporation with executive offices located at 1010 Murry Ridge Lane, Murrysville, PA 15668-8525. Unless the context indicates otherwise, reference in this Annual Report to the "Company" or "Respironics" refers to Respironics, Inc. and its domestic and foreign subsidiaries. Unless the context indicates otherwise, reference in this Annual Report to "fiscal year" refers to the twelve-month period ending on June 30 of the year indicated.

In April 2002, the Company acquired 100% of the outstanding common stock of Novamatrix Medical Systems Inc. ("Novamatrix"), a leading cardiorespiratory monitoring company that developed, manufactured, and marketed proprietary state-of-the-art noninvasive monitors, sensors, and disposable accessories along with developmental care products for premature infants. The Company issued approximately 2,400,000 shares of its common stock to the former stockholders of Novamatrix in exchange for their Novamatrix shares and reserved approximately 509,000 shares of its common stock for future issuance upon exercise of options and warrants issued in exchange for Novamatrix options and warrants outstanding. The total value of the Company's shares issued and reserved for issuance (net of proceeds from exercise of options and warrants) in the transaction was approximately \$81.0 million. The results of operations of Novamatrix are included in the Company's consolidated income statement beginning on the acquisition date, April 12, 2002.

In May 2002, the Company acquired 60% of the outstanding common stock of Fuji, RC Co., Ltd. ("Fuji"), a leading provider of homecare and hospital products and services for respiratory-impaired patients in Japan, and entered into an agreement to purchase all of the remaining outstanding shares of Fuji in a multiple step acquisition by December 31, 2006. The base cash purchase price for all of the outstanding Fuji shares is approximately \$12 million, with provisions for additional payment to one of the shareholders of Fuji to be made based on operating performance of Fuji over the next four years. The results of

Edgar Filing: RESPIRONICS INC - Form 10-K

operations of Fuji, net of minority interest, are included in the Company's consolidated income statement beginning on the acquisition date, May 31, 2002. See Note O to the Consolidated Financial Statements for more information about these acquisitions.

In July 1999, the Company announced a major restructuring of its United States operations. The major components of the restructuring included the closing of the Westminster, Colorado manufacturing facility, the closing of the 19 customer satisfaction centers throughout the United States, the downsizing of the Georgia manufacturing facilities, the opening of a centralized distribution and repair center in Youngwood, Pennsylvania, the realignment of the Company into four divisions with a

4

corresponding management realignment, and a workforce reduction associated with the facility changes and the realignment. The divisional and management realignment took place in July 1999, and the facility changes were completed as planned over the course of fiscal year 2000. The Westminster facility was closed in January 2000 and sold in March 2001. See Note L to the Consolidated Financial Statements for more information about the restructuring, including the costs associated with the restructuring.

The following are registered trademarks of the Company as used in this document: Respiroics, REMstar, REMstar Pro, REMstar Plus, REMstar Auto, Great Performers, Aria, Virtuoso, Duet, Encore, Soft Series Nasal Mask, Tranquility, SmartMonitor, ASSESS, Personal Best, Wallaby, GoldSeal, GEL, Inspiration, Esprit, Asthma Check, OptiHaler, BiPAP, PLV, Solo, OptiChamber, Alice, Stardust, and AsthmaMentor. The following are trademarks of the Company as used in this document: Contour Nasal Mask, Respiroics Millennium, Profile, Encore SmartCard, Simplicity, BiPAP Vision, Comfort Series and BiPAP Synchrony.

Products

The Company's principal products can be divided into three categories: homecare products, hospital products, and asthma and allergy products.

Homecare Products

The Company's homecare products can be separated into five major subcategories: sleep products, non-invasive ventilation products, invasive portable volume ventilation products, oxygen products, and infant management and developmental care products.

Sleep Products. Respiroics believes it is the worldwide market share leader in OSA therapy devices, with a market share in excess of 50%. The Company's primary OSA products include the REMstar Series, Solo, Aria and Virtuoso CPAP units and the BiPAP Duet and the BiPAP S Airway Management Systems, the Tranquility family of CPAP and bi-level units, and related accessories such as humidifiers, masks, tubes, filters and headgear.

The Company's CPAP devices consist of a small, portable air pressurization device, an air pressure control and a mask worn by the patient at home during sleep. The REMstar Series, Solo, and Tranquility CPAP systems are low-cost, innovative OSA therapy devices that meet the Company's strategy of offering units at all key price points and represent standard state-of-the-art CPAP systems that provide high-quality treatment options at an economical price. The Virtuoso and Tranquility Auto CPAP systems utilize innovative technology to

Edgar Filing: RESPIRONICS INC - Form 10-K

monitor the patient's airway and adjust output automatically in order to deliver the appropriate pressure. The REMstar Pro, Aria and Virtuoso CPAP systems, as well as the BiPAP Duet Airway Management System described below, also feature built-in memory to record patient usage and quality of life data. The Company's Encore SmartCard is an easy-to-use device to retrieve this patient data, update air pressure settings, and change modes of operations for certain of the Company's CPAP and bi-level devices by utilizing specially developed data management software that is programmed onto the credit card sized Encore SmartCard.

The BiPAP Duet Airway Management System, the BiPAP Pro, the Tranquility Bi-level System, and the BiPAP S Airway Management System are the Company's bi-level OSA units. These units sense the patient's breathing cycle and adjust the pressure accordingly. The Duet and BiPAP Pro units also contain advanced leak-sensing technology, which improves the unit's pressure adjustment capability. Bi-level units are used to treat severe OSA and are useful in improving acceptance of therapy by patients who have difficulty tolerating CPAP.

The Company also offers both integrated and stand-alone humidifiers as accessories to support its strategy of enhancing patient adherence to the therapy provided by its CPAP and bi-level devices. Humidifying the air that flows into the patient's airway provides more comfortable therapy for certain patients.

5

The Company also provides masks used with CPAP and bi-level devices including the Comfort Series (consisting of the Profile Lite, ComfortSelect, ComfortClassic, and Simplicity masks), the Contour Nasal Mask, the GEL and GoldSeal Masks, the Soft Series Nasal Mask, and Full Face Masks. The Company believes that its nasal mask products were the first masks to adequately seal on a patient's face for nasal CPAP delivery, thereby minimizing patient discomfort and promoting increased patient compliance with prescribed usage. The Company's nasal mask products are all designed to enhance patient comfort by utilizing a variety of shapes and designs and a variety of cushion materials to create a comfortable mask seal around the contours of the face while delivering effective CPAP and bi-level therapy. Full Face Masks address the needs of specific patient groups for whom CPAP and bi-level therapy is delivered most effectively and comfortably through masks that cover the mouth and nose.

Respironics also manufactures and distributes a wide range of technologically advanced computer-based products for use in the diagnosis of sleep related disorders. The Company provides advanced, technically proficient clinical products for use in sleep disorders laboratories (commonly known as a "sleep lab"). The Company also provides products for patient testing in the home which allow clinicians to expand the number of patients who can be served by a traditional sleep disorders lab.

The Company's primary sleep diagnostic product is the Alice System. Alice is a computer-based system for use in sleep labs and other clinical settings. It is capable of recording up to 25 channels of physiological data, which are stored on either a desktop or portable computer prior to permanent storage on optical cartridges. In addition to acquiring and storing the patient's physiological data, the Alice system utilizes physician input and internal algorithms to provide a comprehensive range of reports for clinical analysis. Alice can be used on either infants or adults and separate software programs were developed specifically for each type of patient.

The Company also manufactures and markets Stardust, a palm-sized portable sleep system which monitors up to seven channels of physiological data for up to

Edgar Filing: RESPIRONICS INC - Form 10-K

ten hours per patient and features pre-programmed host software that simplifies data analysis. Among other factors, Stardust is distinguished by its physiological sensors which are specifically designed for use in the home. These sensors record a variety of patient data and the information is subsequently sent to the sleep lab or other clinical setting where it is interpreted by a trained clinician.

The Synchrony Sleep Lab System, consisting of the Synchrony pressure generator and a palm-sized remote control unit is used by clinicians in prescribing therapy for the treatment of adult OSA once a diagnosis has been made.

The Company estimates that in the U.S. there are in excess of 2,500 sleep labs which currently exist at hospitals, other medical centers, and free-standing sites where pulmonologists, technicians and other medical professionals diagnose OSA (as well as other sleep disorders) and then prescribe the appropriate treatment. Such sleep labs provide the most frequent source of patient introductions to the Company's homecare sleep products.

The OSA patient can purchase or rent the Company's OSA therapy products from home medical equipment service provider and dealer locations throughout most of the world. Personnel at each of these locations are generally equipped to train the patient in the product's use and to maintain and service the product. See "Sales, Distribution, and Marketing". The retail price for a CPAP unit ranges from \$1,100 to \$1,600, depending on type of unit, geographical market and whether certain accessories are purchased. The retail price for a bi-level OSA unit generally ranges from \$2,300 to \$3,200, depending on which model is purchased. The Company's sleep diagnostic products are sold through dealers and directly to clinical sites.

Non-invasive Ventilation Products. The Company believes it is the leading manufacturer and marketer of non-invasive ventilatory support devices in the U.S. Such devices are intended to augment the ventilation of a spontaneously breathing patient, but are not intended to satisfy the total ventilatory requirements of the patient.

The Company's principal non-invasive ventilatory support product is the BiPAP Synchrony Ventilatory Support System. This device is a low-pressure, electrically-driven flow generator with an electronic pressure control designed to augment patient breathing

6

by supplying pressurized air to the patient. This device senses the patient's breathing and adjusts its output to assist in inhalation and exhalation. Additionally, the device compensates for mask leaks, which often occur in the delivery of ventilatory support to the patient, thereby providing what the Company believes is a more efficient and consistent non-invasive therapy than competing ventilators. The face masks described above are also used with the non-invasive ventilatory support units.

The Company believes that its non-invasive ventilatory support product has the potential for increasing patient comfort by adapting to the patient's breathing cycles as opposed to requiring the patient to adapt his breathing to the ventilator cycles and by delivering therapy effectively with a patient mask rather than requiring intubation. The retail price for the unit, which ranges from \$6,000 to \$8,000, also compares favorably to the cost of invasive ventilators, which generally retail for \$10,000 to \$28,000.

Insurance coverage by federal government insurance programs for home use

Edgar Filing: RESPIRONICS INC - Form 10-K

in the United States of non-invasive ventilatory support products like the Company's BiPAP Synchrony Ventilatory Support System was modified during fiscal year 2000. The Company's sales of these products for home use in the United States were adversely affected by this modification. The Company expects that opportunities for significant growth in its sales of non-invasive ventilatory support units for home use in the United States are likely to continue to be limited. See "Business -- Third Party Reimbursement" for additional information.

Invasive Ventilation Products. The Company believes that it is one of the leading manufacturers and marketers of invasive portable volume ventilators that are used in the home by individuals who are dependent on the ventilators for continuous life support.

The Company's principal invasive portable volume ventilator is the PLV-100, a microprocessor-controlled, electrically-powered unit specifically designed for long-term use in the home and also suitable for transport, short-term, and institutional use. The PLV-100 can be used to ventilate a wide range of patients. The small, lightweight unit delivers volume ventilation through the operation of a piston inside the unit, and it can be powered by normal AC power or DC battery power and can be operated in three different ventilation modes depending on the patient's needs. The unit features a variety of alarms and displays to alert clinicians and caregivers to changes in the patient's pulmonary status or to possible unit malfunction. The Company manufactures and distributes different versions of the PLV-100 for international markets based on language differences, and it also manufactures and distributes a variety of accessories for use with the PLV-100. The PLV-100 unit and related accessories reach end user patients primarily through the Company's network of medical product dealers who purchase or rent the unit from the Company and resell or rent it to end users. In certain limited cases, the Company rents these units directly to end users.

Oxygen Products. The Company's principal oxygen products are oxygen concentrators, which provide a continuous flow of oxygen by separating it from room air with a molecular sieve composed of an inorganic silicate. Oxygen concentrators are generally used in the home by patients who require supplemental oxygen. Supplemental oxygen is prescribed for people with a variety of chronic pulmonary disorders, such as lung cancer, emphysema, bronchitis or acute pneumonia. These individuals generally rent an oxygen delivery system from a home medical equipment dealer. The Company believes it is currently one of the leaders in the manufacture and sale of oxygen concentrators in the United States.

The Company's primary oxygen concentrator product is the Respironics Millennium. This unit is designed to be easy to maintain and service and is suitable for chronic patients in the advanced stages of illness and for the less severe respiratory patient. The Respironics Millennium also features a low sound level and is mobile, both of which are important features for devices such as this that are used in the home.

The Company also manufactures and markets oximeter products for use in the home. The units, which allow the caregiver to take readings of the patient's blood oxygen levels and pulse rate, feature the capability to store up to 18 hours of data.

7

This data can be later downloaded via the Company's software, which prints reports for oximetry analysis.

Infant Management and Developmental Care Products. The Company's primary

Edgar Filing: RESPIRONICS INC - Form 10-K

infant management products are monitoring devices designed for infants at risk for sudden infant death syndrome or "SIDS." SIDS is the sudden unexpected death of an infant which remains unexplained after investigation and is one of the leading causes of death in the United States of infants between one month and one year of age. Despite extensive research, the causes of SIDS remain unknown. High-risk infants who are prescribed home monitors include infants with low birth weight, those who are premature, those who survive serious cardiorespiratory episodes and those born to a family with a SIDS incident history. There are limited alternative monitoring technologies generally available.

The Company's primary infant monitor is the SmartMonitor, a fifth-generation microprocessor-based design that incorporates many aspects of a physiological recorder into the traditional monitor. In addition to sounding an alarm to alert the parents, the SmartMonitor documents patient episodes with an internal electronic memory system, enabling physicians to study up to six channels of patient waveforms in order to assess the medical significance of the alarm episodes and determine the need for continued monitoring or possible hospitalization. The data collected by the SmartMonitor can be transmitted from the home to a clinical center over phone lines or can be extracted from the SmartMonitor using a memory transfer device such as a computer.

The Company also manufactures and markets the Wallaby II Phototherapy System, a cost-effective, home-based alternative to conventional overhead phototherapy lights for treating newborn jaundice, a condition which is caused by elevated levels of bilirubin in the blood and which, in severe cases, can result in brain damage.

The Company also markets the BiliChek Non-Invasive Bilirubin Analyzer, a non-invasive device that measures the level of bilirubin in the blood of infants. The current method of measuring bilirubin levels to diagnose jaundice in infants, the "heel stick," involves drawing blood from the infant and is a painful, costly and time consuming procedure. BiliChek replaces the heel stick by analyzing reflected light shined on an infant's forehead to generate immediate and painless test results at a low cost. The Company has exclusive distribution rights in the United States and Canada for the BiliChek, and the device has received clearance to market from the FDA for infants before, during, and after phototherapy treatment.

The Company also markets developmental care products and services designed to improve the quality of care for premature infants. These developmental care products are designed to meet the unique needs of premature infants, including appropriately-sized infant care products, safety equipment, and specialty feeding and skin care products. The Company also offers related education products and programs. The Company's developmental care products are used in the home and in neonatal and pediatric intensive care units of hospitals.

Sales of homecare products and all related accessories and replacement parts accounted for 83%, 85%, and 84% of the Company's net sales for its fiscal years 2002, 2001, and 2000, respectively.

Hospital Products

The Company has two major hospital product groups: therapeutic devices that assist or control a patient's ventilation; and cardiorespiratory monitoring devices that provide information about a patient's condition.

The Company's primary therapeutic devices are the BiPAP Vision and the Esprit. The BiPAP Vision is a non-invasive ventilatory support device designed specifically for hospital use and features an oxygen module, provides higher

Edgar Filing: RESPIRONICS INC - Form 10-K

flow and pressure functions than the Company's other non-invasive units, and is designed to be easily upgradeable. The BiPAP Vision also includes integrated airway pressure monitoring, an integrated display screen, a disposable circuit, and a mounting stand,

8

all of which are designed to allow the unit to be used more easily in delivering non-invasive ventilatory support in the hospital environment.

The Company also manufactures and markets the Esprit, a ventilator designed for use in the hospital and institutional settings. Esprit is designed to effectively deliver both invasive and noninvasive ventilation, thus eliminating the need to use two separate ventilators for one patient and allowing it to be used throughout the continuum of patient care. Esprit features a graphical user interface with an infrared touch screen, alarm and status indicators designed to allow rapid assessment of alarm conditions and patient status, and is designed to be easily upgradeable.

The Company also manufactures, distributes, and rents several other hospital ventilation products, including a version of the PLV-100 designed more specifically for institutional use, and a variety of masks, tubing and headgear similar to those used in the homecare market described above along with certain other accessories specifically designed for hospital and institutional use.

The Company also manufactures and markets cardiorespiratory monitors, sensors and related disposable accessories. These electronic devices provide continuous measurements of a patient's cardiac output, carbon dioxide, oxygen saturation, and respiratory mechanics parameters. The sensors for the Company's devices are designed so that this patient data can be gathered noninvasively. Noninvasive monitoring offers advantages over invasive monitoring, including a reduced likelihood of infection and other associated complications that can result from invasive monitoring. The Company's cardiorespiratory monitoring devices are used in hospital operating rooms, intensive care units, emergency departments, and while transporting patients to or within the hospital.

Sales of hospital products and accessories accounted for 12%, 10%, and 10% of the Company's net sales for fiscal years 2002, 2001, and 2000, respectively.

Asthma and Allergy Products

The market for asthma devices is comprised primarily of peak flow meters and drug delivery systems, including spacer devices. A peak flow meter provides an objective measure of lung function and is used by the patient at home to assist in the management of asthma. A spacer, when used with a metered dose inhaler ("MDI"), facilitates the delivery of asthma medications.

The Company believes that it is currently the national leader in the sale of peak flow meters, marketing products that include the ASSESS, AsthmaMentor, and Asthma Check peak flow meters and the portable peak flow meter, Personal Best. The Company also markets two spacer products known as OptiChamber and OptiHaler. The revised National Asthma Education and Prevention Program ("NAEPP") Guidelines issued in March 1997 have placed further emphasis on the use of peak flow meters and spacers to ensure effective asthma management. OptiChamber represents an important growth area based upon NAEPP's expanded indications for MDI anti-inflammatory therapy, including new recommendations for use with children under five years of age.

Edgar Filing: RESPIRONICS INC - Form 10-K

The Company also distributes several models of medication nebulizers, which dispense medication in a fine mist for inhalation deep into the lungs, under the trade name Inspiration. The primary uses for nebulizers have been in the treatment of respiratory diseases, such as emphysema and chronic bronchitis, and conditions such as asthma or allergies. The Company's models utilize a compressor to direct a flow of air through the nebulizer chamber which contains medication in liquid form. An increase in the number of available respiratory medications in recent years, coupled with the cost and efficacy of aerosol delivery methods, has contributed to the growth of this market.

A variety of distribution channels are used for asthma and allergy products, including specialty hospital dealers, homecare dealers, and, to a lesser extent, pharmaceutical companies and retail pharmacies.

Sales of all asthma and allergy products accounted for 5%, 5%, and 6% of the Company's net sales for its fiscal years 2002, 2001, and 2000, respectively.

9

Manufacturing and Properties

The Company owns or leases its manufacturing, office and warehouse facilities. The Company's major facilities and their primary uses are summarized below:

	Square Feet	Owned/Leased
United States:		
Murrysville, Pennsylvania (offices)	55,000	Owned
Murrysville, Pennsylvania (offices)	20,000	Leased
Murrysville, Pennsylvania (manufacturing)	116,000	Owned
Plum Borough, Pennsylvania (offices and warehouse)	22,000	Leased
Kennesaw, Georgia (manufacturing)	129,000	Leased
Carlsbad, California (manufacturing)	85,000	Leased
Wallingford, Connecticut (manufacturing)	53,000	Leased
Cedar Grove, New Jersey (offices)	10,333	Leased
Youngwood, Pennsylvania (warehouse)	86,000	Leased
Edison, New Jersey (warehouse)	6,800	Leased
Houston, Texas (warehouse)	7,200	Leased
Concord, California (warehouse)	6,800	Leased
La Mirada, California (warehouse)	6,400	Leased
International:		
Hong Kong (offices)	15,500	Leased
Shenzhen, China (manufacturing)	99,700	Leased
Subic Bay, Philippines (manufacturing)	22,700	Leased
Tokyo, Japan (offices)	4,600	Leased
Saitama City, Japan (warehouse)	7,400	Leased
Herrsching, Germany (offices and warehouse)	18,590	Leased
Nantes, France (offices and warehouse)	6,100	Leased
Paris, France (offices)	3,400	Leased

The Company also has approximately 50 sales and service centers

Edgar Filing: RESPIRONICS INC - Form 10-K

throughout Japan, each of which is approximately 700 square feet in size and is leased.

Operations in the Far East and Europe are subject to the risks normally associated with foreign operations including, but not limited to, foreign currency fluctuations, possible changes in export or import restrictions and the modification or introduction of other governmental policies with potentially adverse effects. The change of control in Hong Kong from British to Chinese rule has not affected the Company's operations.

The Company believes that its present facilities are suitable and adequate for its current and presently anticipated future needs. While several facilities are extensively utilized, additional productive capacity is available through a variety of means including augmenting the current partial second shift work schedule at the United States facilities. Rental space, which the Company believes is readily available and reasonably priced near each current location, could be utilized as well. The Company also owns land adjacent to the site on which the Murrysville manufacturing facility listed above is located. Future expansion in Murrysville, if needed, could take place on this land.

In March 2001, the Company sold its Westminster, Colorado facility that had been closed as part of the Company's July 1999 restructuring. A gain of approximately \$2,000,000 was recorded on the sale, and the long-term debt related to the facility was repaid. See Note L to the Consolidated Financial Statements for additional information.

10

The Company generally performs all major assembly work on all of its products. It manufactures many of the plastic components for its face mask products and uses subcontractors to supply certain other components. The Company believes that the raw materials for nearly all of its products are readily available from a number of suppliers.

Sales, Distribution and Marketing

The Company sells and, in some cases, rents its products primarily to home medical equipment service providers and hospital dealers. These parties in turn resell and rent the Company's products to end-users. The Company also sells certain of its products directly to hospitals. The Company's products reach its customers in the United States primarily through the Company's field network, which consists of 36 national and regional management employees, 121 direct sales representatives and sales support specialists, 40 independent manufacturers' representatives, and over 5,000 medical products distributors (also referred to as "dealers").

The Company manages its U.S. dealer network through the direct sales force and independent manufacturers' representatives. The Company's sales management team includes a Vice President of Homecare Sales, a Vice President of Hospital Sales and Marketing, a Vice President of Hospital Sales, twenty-two Regional Sales Managers, and eleven National Accounts Managers. This team directs the activities of the independent manufacturers' representatives, direct sales representatives, and sales support specialists.

The Company's international sales efforts are conducted through a President of International Sales, a Vice President of Europe, Africa, and Middle East Sales, a Vice President of Asia Pacific Sales and Marketing, and a Director of Latin American Sales and Marketing. The Company also has direct sales representatives and a customer satisfaction staff in the Far East, Germany and France. Total international sales force for the Company, including approximately

Edgar Filing: RESPIRONICS INC - Form 10-K

135 sales representatives from the recently acquired Fuji, is approximately 173 individuals, including management, account managers, sales support specialists, and direct sales representatives. The Company's international sales employees sell products from all three major product groups. International sales accounted for approximately 20% of the Company's net sales for fiscal years 2002 and 2001, and 21% for fiscal year 2000.

In November 1999, the Company introduced its new program-oriented approach to doing business with homecare dealer customers (who are also referred to as "providers"). These "Power Programs for Providers" incorporate specific products with a package of diagnostic tools and other educational materials. The programs are designed to support a provider's desire to offer the finest care possible while assisting the provider in growing its business. The Company currently offers five Power Programs: Sleep Management, Chronic Respiratory Management, Ventilation Management, Asthma, Allergy, and Sinusitis Management, and Infant Developmental Care.

The Company's marketing organization is currently staffed by Product Managers, who are assigned to each of the Company's principal product groups. The Product Managers stay abreast of changes in the marketplace, with an emphasis on product use specifications, features, price, promotions, education, training and distribution.

The Company's U.S. dealer customer base (which ranges in size from large, publicly held dealers with several hundred branch locations to small, owner-operated dealers with one location) continues to undergo consolidation, particularly among dealers specializing in homecare products. The impact on the Company of this customer consolidation is likely to continue to be reduced selling prices for the Company's products as a result of greater purchasing power and market dominance enjoyed by larger customers.

During the fiscal year ended June 30, 2002, one customer accounted for 10% of net sales. While other similar national homecare dealer customers in the U.S. accounted individually for less than 10% of sales, these customers collectively constitute an important market for the Company's products.

11

The Company offers leasing programs to certain of its customers through arrangements with independent leasing companies. In some cases, these arrangements call for the Company to be contingently liable, in the event of a customer default, to the leasing companies for certain unpaid installment receivables initiated by or transferred to the leasing companies. The Company's total exposure for unpaid installment receivables under these leasing programs was approximately \$30,254,000 and \$22,670,000 at June 30, 2002 and 2001, respectively. Approximately \$11,826,000 of the June 30, 2002 balance consisted of installment receivables acquired as part of the Novamatrix acquisition. See Note K to the Consolidated Financial Statements for additional information.

Competition

The Company believes that the principal competitive factors in all of its markets are product and service performance and innovation, efficient distribution and competitive price. Price competition has become more intense in the last several years. In the case of a number of the Company's and its competitors' products, patent protection is becoming more prevalent and of increasing competitive importance. The Company competes on a product-by-product basis with various other companies, some of which have significantly greater financial and marketing resources and broader product lines.

Edgar Filing: RESPIRONICS INC - Form 10-K

The Company believes that it is a U.S. market leader in each major market in which it competes: sleep disorders, chronic obstructive pulmonary disease, asthma and allergy, and infant care products. However, other manufacturers, including other larger and more experienced manufacturers of home healthcare products, are active in these markets and the Company expects that competition will increase. In its major product lines, the Company competes with two principal competitors, Mallinckrodt Inc. ("Mallinckrodt") (which was acquired by Tyco International Ltd ("Tyco") in October 2000) and ResMed, Inc. ("ResMed"). Mallinckrodt, which is the Company's largest major competitor and has the greatest financial resources of the Company's competitors, offers an array of products which compete with many of the Company's major products. ResMed competes with the Company in the OSA and non-invasive ventilatory support markets. The Company also competes with Invacare Corp., Vital Signs, Inc., Monaghan Medical Corp., Fisher & Paykel Healthcare Corp. Ltd., and with divisions of Sunrise Medical, Inc. Additionally, the Company competes with a number of foreign manufacturers, primarily in their local overseas markets and to a lesser extent in the domestic market.

Similar to the Company's customer base, the medical device manufacturing industry is also undergoing consolidation. Several of the Company's competitors have been involved in acquisitions, most notably the acquisition of Mallinckrodt by Tyco and the February 2001 acquisition by ResMed of MAP, a German company that manufactures, among other things, CPAP devices. The impact on the Company of this competitor consolidation is likely to be greater competition from medical device manufacturers which can utilize the financial and technical resources that may be made available as a result of the consolidation.

Research and Development

The Company believes that its ability to identify product opportunities, to respond to the needs of cardiopulmonary and other physicians and their patients in the treatment of respiratory and other disorders and to incorporate the latest technological innovations into its medical products has been and will continue to be important to its success. The Company's research and development efforts are focused on understanding the problems faced by cardiopulmonary physicians and their patients' needs and on maintaining the Company's technological leadership in its core product areas. The Company maintains both formal and informal relationships with physician practitioners and researchers to supplement these research and development efforts. The Company's research and development efforts enable it to capitalize on opportunities in the respiratory medical product market by upgrading its current products as well as developing new products.

12

The Company conducts substantially all of its research and development for existing and potential new products in the U.S. The Company currently employs approximately 255 engineers, technicians, and support personnel in such activities. The research and development staff performs overall conceptual design work for all products and the design work related to the manufacturing, engineering and tooling for products manufactured by the Company. The Company spent approximately \$17,317,000 (3% of net sales) in fiscal year 2002, \$15,281,000 (4% of net sales) in fiscal year 2001, and \$16,815,000 (5% of net sales) in fiscal year 2000 to support product enhancement and new product development.

New product introductions in all of the Company's core product areas took place during fiscal years 2000, 2001, and 2002, including next generation CPAP units, such as a new auto CPAP device, the BiPAP Synchrony, the BiPAP Pro,

Edgar Filing: RESPIRONICS INC - Form 10-K

the H2 Heated Humidifier, new sleep diagnostic products, a variety of new face mask products, and several new asthma devices. The Company expects to release a variety of new devices in its core product areas in fiscal year 2003. In some cases, initial distribution has been, and will be, conducted in international markets until regulatory clearance to market in the U.S. is obtained. See "Regulatory Matters."

In addition to its development efforts in its core product areas, the Company is actively pursuing product development activities in a variety of new markets, including congestive heart failure, tracheal gas insufflation, and humidification.

Research has indicated that as many as 50% of the patients with congestive heart failure also have obstructive sleep apnea or Cheyne-Stokes Respiration ("CSR"), a form of apnea with abnormal breathing patterns. The Company believes that if both these conditions are identified and treated, the apneas associated with each condition can be eliminated and the quality of life and overall health of these patients can be improved. Additionally, the Company believes that positive pressure therapy may eliminate CSR events and their effects on heart failure, reduce the circulatory congestion associated with heart failure, and improve the pumping efficiency of the heart into the patient's circulatory system. Research, including clinical trials, is being conducted to evaluate the long-term effects of positive pressure therapy on the heart. The Company is also in discussion with the FDA regarding the technical and clinical information that would be necessary to market a device for certain congestive heart failure applications.

The Company is also developing a system focused on reducing carbon dioxide blood gas levels in many ventilator patients with elevated carbon dioxide levels. The Company is currently planning to introduce this tracheal gas insufflation system in calendar year 2004 pending FDA clearance to market.

The Company is also developing a hospital humidification system designed to provide optimal humidification at lower usage cost than current products, with a goal of introduction in fiscal year 2003; initial introductions to occur in international markets and later in the U.S. pending FDA clearance to market.

The Company is also continuing its research on the treatment of insomnia.

Patents, Trademarks and Licenses

The Company seeks patent protection for certain of its products through the prosecution and acquisition of patents and exclusive licensing arrangements. In addition, the Company aggressively defends its patents when infringed by other companies. The Company currently has approximately 278 U.S. and foreign patents and has additional U.S. and foreign patent applications pending. Some of these patents and patent applications relate to significant aspects and features of the Company's products. Eighteen of these patents expire in the next five years as follows: three expire in fiscal year 2003, three expire in fiscal year 2004, four expire in fiscal year 2005, three expire in fiscal year 2006, and five expire in fiscal year 2007. The Company believes that the expiration of these patents will not have a material adverse impact on its competitive position.

The Company also has approximately 275 registered U.S. and foreign trademarks and has additional U.S. and foreign trademark applications pending.

The Company is a party to a legal action relating to the patents of its competitors. See "Item 3 - Legal Proceedings" for more information regarding this action.

Regulatory Matters

The Company's products are subject to regulation by, among other governmental entities, the FDA and corresponding foreign agencies. The FDA regulates the introduction, manufacture, advertising, labeling, packaging, marketing and distribution of and recordkeeping for such products. In manufacturing and marketing its products, the Company must comply with FDA regulations and is subject to various other FDA recordkeeping and reporting requirements and to inspections by the FDA. The testing for and preparation of required applications can be expensive, and subsequent FDA review can be lengthy and uncertain. The FDA also regulates the clinical testing of medical devices. Moreover, clearance or approval, if granted, can include significant limitations on the indicated uses for which a product may be marketed. Failure to comply with applicable FDA regulations can result in fines, civil penalties, suspensions or revocation of clearances or approvals, recalls or product seizures, operating restrictions or criminal penalties. Delays in receipt of, or failure to receive, clearances or approvals for the Company's products for which such clearances or approvals have not yet been obtained would adversely affect the marketing of such products in the U.S. and could adversely affect the results of future operations.

The Company must obtain FDA or foreign regulatory approval or clearance for marketing the Company's new devices prior to their release. There are two primary means by which the FDA permits a medical device to be marketed. A manufacturer may seek clearance for the device by filing a 510(k) premarket notification with the FDA. To obtain such clearance, the 510(k) premarket notification must establish that the device is "substantially equivalent" to a device that has been legally marketed under a 510(k) notification or was marketed before May 28, 1976. The manufacturer may not place the device into commercial distribution in the U.S. until a substantial equivalence determination notice is issued by the FDA. The FDA, however, may determine that the proposed device is not substantially equivalent, or require further information, such as additional test data or clinical data, or require the Company to modify its product labeling, before it will make a finding of substantial equivalence. The process of obtaining FDA clearance of a 510(k) premarket notification, including testing, preparation of the 510(k) premarket notification and subsequent FDA review, can take a number of years and require the expenditure of substantial resources.

If a manufacturer cannot establish to the FDA's satisfaction that a new device is substantially equivalent to a legally marketed device, it will have to seek approval to market the device through the premarket approval application ("PMA") process. This process involves preclinical studies and clinical trials. The process of completing clinical trials, submitting a PMA and obtaining FDA clearance takes a number of years and requires the expenditure of substantial resources. In addition, there can be no assurance that the FDA will approve a PMA. The Company's export activities and clinical investigations also are subject to the FDA's jurisdiction and enforcement.

Foreign regulatory approvals vary widely depending on the country. The Company has received ISO 9001 certification for its Murrysville, Kennesaw, Carlsbad, Wallingford, Cedar Grove, and Shenzhen facilities from the International Organization of Standards, a quality standards organization based in Geneva, Switzerland. The Company has also received authorization for the same facilities, under the European Union's Medical Device Directives, to affix the "CE Mark" to the Company's products marketed throughout the world. The primary component of the certification process was an audit of the facilities' quality

Edgar Filing: RESPIRONICS INC - Form 10-K

systems conducted by an independent agency authorized to perform conformity assessments under ISO guidelines and the Medical Device Directives. Since receiving its original ISO 9001 certification, these facilities have undergone periodic update audits by such independent agencies.

Third Party Reimbursement

The cost of a significant portion of medical care in the U.S. is funded by government and private insurance programs, such as Medicare, Medicaid and corporate health insurance programs including health maintenance organizations and managed care organizations. The Company's future results of operations and financial condition could be negatively affected by adverse changes made in the reimbursement policies for medical

14

products under these insurance programs. If such changes were to occur, the ability of the Company's customers (medical product distributors and dealers) to obtain adequate reimbursement for the resale or rental of the Company's products could be reduced. In recent years, limitations imposed on the levels of reimbursement by both government and private insurance programs have become more prevalent.

The Company has obtained "procedure codes" for its homecare products from the Centers for Medicare and Medicaid Services ("CMS") (formerly known as the Healthcare Financing Administration). These procedure codes enhance the ability of medical product distributors and dealers to obtain reimbursement for providing products to patients covered by Medicare. In addition, many private insurance programs also use the CMS procedure code system. However, reimbursement levels can be reduced after a procedure code has been established.

The amount of reimbursement that a hospital can obtain under the Medicare diagnosis related group ("DRG") payment system for utilizing the Company's products in treating patients is a primary determinant of the revenue that can be realized by medical product distributors and dealers who resell or rent the Company's hospital products. Many private insurance programs also utilize the Medicare DRG system. The various uses of the Company's hospital products to treat patients are provided within the DRG system. The levels of reimbursement under the DRG system are also subject to review and change.

Employees

The Company currently has approximately 2,600 employees, including approximately 800 hourly employees in the U.S. and 600 hourly employees in the Far East. None of the Company's employees are covered by collective bargaining agreements. The Company considers its labor relations to be good and has never suffered a work stoppage as a result of a labor conflict.

Financial Information About Foreign and Domestic Operations and Export Sales

Financial information concerning foreign and domestic operations and export sales is discussed in Item 1, "Business - Sales, Distribution and Marketing", and set forth in Note I of the Consolidated Financial Statements included in this Annual Report.

Item 2. Properties

Information with respect to the location and general character of the principal properties of the Company is included in Item 1, "Business -

Edgar Filing: RESPIRONICS INC - Form 10-K

Manufacturing and Properties."

Item 3. Legal Proceedings

U.S. ResCare Litigation

In January 1995 ResCare (now ResMed Limited; hereinafter "ResCare") filed an action (the "California suit") against the Company in the United States District Court for the Southern District of California alleging that in the manufacture and sale in the United States of nasal masks and CPAP systems and components, the Company infringes three U.S. patents, two of which are owned by and one of which is licensed to ResCare (the "ResCare patents"). The patents involved in the California suit deal with basic CPAP, mask applications and a delay timer feature of ResCare's CPAP devices. In the complaint, ResCare seeks preliminary and permanent injunctive relief, an accounting for damages and an award of three times actual damages because of the Company's alleged willful infringement of the ResCare patents.

15

In its answers to ResCare's complaint, the Company denied, in all material respects, the allegations of the complaint. The Company also filed an action in the United States District Court for the Western District of Pennsylvania against ResCare seeking declaratory judgments that the ResCare patents in issue are either invalid or unenforceable or that the Company does not infringe the patents.

Also as part of its response to the ResCare complaint, the Company filed a motion in the United States District Court for the Southern District of California seeking to transfer the California suit to the United States District Court for the Western District of Pennsylvania and to consolidate the two suits. The motion was granted and the cases have been consolidated in Pittsburgh, Pennsylvania.

In June 1996 ResCare filed another action against the Company in the United States District Court for the Western District of Pennsylvania alleging that in the manufacture and sale in the United States of CPAP systems, the Company infringes a fourth U.S. patent that had been recently issued to ResCare relating to the delay timer technology component used in CPAP systems. In this additional litigation, ResCare seeks similar damages as in the pre-existing patent suits. This suit was consolidated, upon the Company's motion, with the pre-existing patent suits described above and discovery is now proceeding on the consolidated action. No trial date has been set.

The Court has granted the Company's various motions for summary judgment and held that the Company does not infringe any of ResCare's four patents at issue. ResCare may seek an appeal of those decisions. In any event, the Company intends to continue to pursue its claims that the ResCare patents are invalid or unenforceable.

Other

The Company is, as a normal part of its business operations, a party to other legal proceedings in addition to those described above. Legal counsel has been retained for each proceeding and none of these proceedings is expected to have a material adverse impact on the Company's results of operations or financial condition.

Item 4. Submission of Matters to a Vote of Security Holders.

Edgar Filing: RESPIRONICS INC - Form 10-K

During the fourth quarter of the fiscal year 2002, no matters were submitted to a vote of security holders.

PART II

Item 5. Market For Registrant's Common Equity and Related Shareholder Matters.

As of June 30, 2002, 36,885,795 shares of the Company's common stock were issued and outstanding, of which 3,592,725 are held in treasury. The common stock is traded in the over-the-counter market and is reported on the NASDAQ National Market system under the symbol "RESP". As of September 23, 2002, there were 2,252 holders of record of the Company's common stock.

On June 21, 2002, the Company issued shares of common stock to Photios T. Paulson, as a warrant holder for shares in Novamatrix Medical Systems Inc. ("Novamatrix") which was converted into a warrant to acquire the Company's common stock in connection with the acquisition of Novamatrix. In consideration for the issuance of 2,541 shares, Photios T. Paulson paid an exercise price of \$26,248.53. The issuance of shares was exempt from the registration requirements of the Securities Act of 1933 under section 4(2) as a transaction not involving any public offering.

16

The Company has never paid a cash dividend with respect to its common stock and does not intend to pay cash dividends in the foreseeable future.

High and low sales price information for the Company's common stock for the applicable quarters is shown below.

Fiscal year ended June 30, 2002:

	First -----	Second -----	Third -----	Fourth -----
High	\$37.00	\$37.05	\$37.88	\$36.36
Low	\$27.75	\$30.54	\$23.79	\$30.81

Fiscal year ended June 30, 2001:

	First -----	Second -----	Third -----	Fourth -----
High	\$19.13	\$34.00	\$30.75	\$35.13
Low	\$16.25	\$15.69	\$22.94	\$26.19

Item 6. Selected Financial Data

(Dollars in thousands except per share data)

Income Statement Data:

Year Ended June 30

Edgar Filing: RESPIRONICS INC - Form 10-K

	2002 ----	2001 ----	2000 ----	1999 ----	1998 ----
Net sales	\$ 494,919	\$ 422,438	\$ 368,184	\$ 357,571	\$ 351,576
Cost of goods sold	260,795	223,362	196,520	186,487	180,650
Cost of goods sold - restructuring charges	0	725	8,710	0	0
	-----	-----	-----	-----	-----
	234,124	198,351	162,954	171,084	170,926
General and administrative expense	60,719	50,126	48,754	48,521	37,200
Sales, marketing and commission expense	86,189	72,428	62,772	60,899	65,560
Research and development expense	17,317	15,281	16,815	16,714	20,225
Integration and restructuring charges (credits)	2,288	(1,909)	20,486	2,415	0
Impairment charge	2,006	0	0	0	0
Merger related costs	0	0	0	0	40,751
Costs associated with unsolicited offer to acquire Healthdyne Technologies, Inc.	0	0	0	0	650
Interest expense	3,011	7,546	6,945	5,206	4,189
Other income	(1,442)	(1,029)	(1,394)	(1,127)	(1,513)
	-----	-----	-----	-----	-----
Income before income taxes	64,036	55,908	8,576	38,456	3,864
Income taxes	25,619	22,337	2,824	15,395	5,689
	-----	-----	-----	-----	-----
Net income (loss)	\$ 38,417	\$ 33,571	\$ 5,752	\$ 23,061	\$ (1,825)
	=====	=====	=====	=====	=====
Earnings (loss) per share	\$ 1.20	\$ 1.09	\$ 0.19	\$ 0.72	\$ (0.06)
	=====	=====	=====	=====	=====
Weighted average number of shares used in computing earnings per share	32,008	30,886	30,004	31,956	32,098

17

Balance Sheet Data:

	June 30				
	2002 ----	2001 ----	2000 ----	1999 ----	1998 ----
Working capital	\$198,966	\$171,985	\$155,095	\$155,336	\$137,550
Total assets	547,450	367,295	352,577	343,585	318,320
Total long-term obligations	59,502	80,055	108,095	99,374	69,316
Shareholders' equity	367,720	235,268	191,106	194,521	200,840

There were no cash dividends declared during any of the periods presented in the above table.

18

Item 7. Management's Discussion and Analysis of Results of Operations and

Financial Condition

Results of Operations

Net sales for fiscal year 2002 were \$494,919,000, representing a 17% increase in sales over the \$422,438,000 recorded in fiscal year 2001. Fiscal year 2001 net sales represented a 15% increase in net sales over the \$368,184,000 recorded in fiscal year 2000. Increases in unit and dollar sales for the Company's obstructive sleep apnea therapy devices (the Company's largest product line) and oxygen concentrator devices, as well as increases in the sales of masks and accessories, helped to drive the increase in sales for both fiscal years. These product lines, along with ventilation devices, comprise the major part of the Company's homecare product offerings. Sales of the Company's hospital products, particularly the Vision(TM) and Esprit(R) ventilators, also contributed to the increase in sales in the 2002 fiscal year. During fiscal year 2001, sales of the Company's hospital products also increased compared to fiscal year 2000, including unit and dollar increases for the Company's Esprit(R) ventilator.

Fiscal year 2002 sales included approximately \$12.7 million of net sales for Novamatrix Medical Systems Inc. ("Novamatrix"), a leading cardiorespiratory monitoring company acquired by the Company during the fourth quarter of fiscal year 2002. Included in the sales from Novamatrix were approximately \$9.5 million of net sales for cardiorespiratory hospital devices and approximately \$3.2 million of net sales for developmental infant care products. Fiscal year 2002 sales also include one month of sales for the distribution company Fuji, RC Co., Ltd ("Fuji"), in which the Company obtained a majority interest in the fourth quarter of fiscal year 2002. The Company's results of operations include the results from both companies since the acquisition dates. For additional information regarding Novamatrix and Fuji, see the Financial Condition, Liquidity, and Capital Resources section of this Management's Discussion and Analysis and Note O to the Consolidated Financial Statements.

The Company's gross profit was 47% for fiscal years 2002 and 2001, and 44% for fiscal year 2000. Excluding the impact of purchase accounting adjustments and restructuring charges described below, the Company's gross profit was 48% of net sales for fiscal year 2002 compared to 47% of net sales for fiscal years 2001 and 2000. The increase in gross profit percentage for fiscal year 2002 compared to the prior years was primarily due to higher revenue, the impact of higher gross margin from acquired entities, and a shift in sales mix.

General and administrative expenses, including the additions to the allowance for doubtful accounts described below, were \$60,719,000 (12% of net sales) for fiscal year 2002, \$50,126,000 (12% of net sales) for fiscal year 2001, and \$48,755,000 (13% of net sales) for fiscal year 2000. The increase in absolute dollars of expense for fiscal year 2002 was due in part to additional general and administrative expenses for one of the Company's two acquisitions, Novamatrix. The increases in expenses for all the periods presented were due primarily to increased information technology department expenses, credit and collection department expenses, and other spending consistent with the growth of

Edgar Filing: RESPIRONICS INC - Form 10-K

the Company's business. Partially offsetting these increases in expenses in all three fiscal years were lower operating expenses due to the Company's previous restructuring efforts. Fiscal year 2001 general and administrative expenses includes a previously disclosed addition to the allowance for doubtful accounts of \$1,200,000 (less than 1% of net sales) to address the potential uncollectability of the balance due from one of the Company's significant hospital distribution customers which ceased operations during the year. The fiscal year 2000 general and administrative expenses includes an addition to the allowance for doubtful accounts of \$4,500,000 (1% of net sales) related to a previously disclosed filing by one of the Company's major customers under Chapter 11 of the U.S. Bankruptcy Code. The Company's total balance due from the customer at the date of the Chapter 11 filing was approximately \$4,500,000.

Sales, marketing and commission expenses were \$86,189,000 (17% of net sales) for fiscal year 2002 as compared to \$72,428,000 (17% of net sales) for fiscal year 2001 and \$62,772,000 (17% of net sales) for fiscal year 2000. The increases in absolute dollars of expense for fiscal years 2002 and 2001 were due primarily to increased sales (resulting in higher commission and sales bonus expenses) and increased sales,

19

marketing, product support, and service activity levels across the Company's product lines, partially offset by lower operating expenses due to the Company's previous restructuring efforts. Fiscal year 2002 also included additional sales, marketing and commission expenses for Novamatrix and Fuji since their acquisition dates.

Research and development expenses were \$17,317,000 (3% of net sales) for fiscal year 2002, as compared to \$15,281,000 (4% of net sales) for fiscal year 2001 and \$16,815,000 (5% of net sales) for fiscal year 2000. The increase in absolute dollars for the current fiscal year was due to the Company's continuing commitment to research, development and new product introduction. The current fiscal year also included additional research and development expense for Novamatrix. The decrease in absolute dollars of expense for fiscal year 2001 compared to fiscal year 2000 was due primarily to the timing of certain research and development projects and the impact of certain new products transitioning from development into production. Significant product development efforts are ongoing, and new product launches in all of the Company's major product lines took place in fiscal years 2002, 2001, and 2000, with additional new product launches scheduled for fiscal year 2003. In the current fiscal year, new products such as the REMstar(R) Auto CPAP (Continuous Positive Airway Pressure) device, the BiPAP(R) Pro bi-level obstructive sleep apnea therapy unit, the H2 Heated Humidifier (the latest addition to the Company's line of heated humidifiers for CPAP and bi-level devices), and two new masks, the ComfortClassic(TM) Nasal Mask and the ComfortSelect(TM) Nasal Mask were introduced. Additional development work and clinical trials are being conducted in certain product areas outside the Company's current core products or patient groups, including products designed to treat congestive heart failure.

As part of the acquisition of Novamatrix, during the fourth quarter of fiscal year 2002, the Company incurred a non-recurring purchase accounting adjustment in cost of goods sold of \$1,653,000 related to reversing acquisition date inventory fair market value adjustments as inventory was sold subsequent to the acquisition. Also incurred during the fourth quarter of fiscal year 2002 were non-recurring charges of \$2,288,000 for integration and restructuring costs related to the Novamatrix acquisition, primarily for the elimination and centralization of certain duplicate back office functions. During the fourth quarter of fiscal year 2002, the Company also incurred an impairment charge of \$2,006,000 representing the write-off of intangible assets, inventory, and fixed

Edgar Filing: RESPIRONICS INC - Form 10-K

assets related to an oxygen monitoring technology development project that was cancelled based in part on the results of a review of that technology by engineers at Novamatrix. See the Financial Condition, Liquidity, and Capital Resources section of this Management's Discussion and Analysis and Note O to the Consolidated Financial Statements for additional information regarding these non-recurring charges.

During fiscal year 2000, the Company incurred a charge of \$29,200,000 related to a previously disclosed restructuring of its U.S. operations. This restructuring included facility closings and downsizings, a management realignment, and a workforce reduction. The primary components of these costs were severance and employment related costs (\$6,300,000), asset write-downs to reflect decisions made regarding product, facility, and systems rationalization (\$8,900,000), and lease buyouts related to facility rationalizations and other direct expenses of the restructuring (\$14,000,000). Approximately \$8,700,000 of these charges relate to inventory write-offs in connection with product rationalizations and have been reported as a separate component of cost of goods sold.

During fiscal year 2001, the Company incurred additional restructuring charges of \$800,000 related to the restructuring described above, primarily for inventory write-offs of discontinued products. Also during fiscal year 2001, the Westminster, Colorado facility, which had been closed in the restructuring, was sold for a gain of approximately \$2,000,000 and debt on the facility totaling approximately \$4,100,000 was repaid. See the Financial Condition, Liquidity, and Capital Resources section of this Management's Discussion and Analysis and Note L to the Consolidated Financial Statements for additional information regarding the restructuring.

During the fiscal year ended June 30, 2000, the Company reached an agreement with the Internal Revenue Service regarding examinations of federal income tax returns for certain of the Company's U.S. entities for fiscal years 1996 through 1998. Based on this agreement, the Company recorded a one-time reduction in income tax liability and income tax expense of \$1,643,000 during fiscal year 2000.

20

The Company's effective income tax rate (excluding the one-time reduction in income tax liability described above) was 40% for fiscal years 2002, 2001, and 2000. The Company's effective tax rate for fiscal year 2000 including the item above was 33%.

As a result of the factors described above, the Company's net income was \$38,417,000 (8% of net sales) or \$1.20 per diluted share for fiscal year 2002 as compared to \$33,571,000 (8% of net sales) or \$1.09 per diluted share for fiscal year 2001 and \$5,752,000 (2% of net sales) or \$0.19 per diluted share for fiscal year 2000.

Excluding the impact of the various non-recurring items described above, the Company's net income was \$42,270,000 (9% of net sales) or \$1.32 per diluted share for fiscal year 2002 as compared to \$33,581,000 (8% of net sales) or \$1.09 per diluted share for fiscal year 2001 and \$25,363,000 (7% of net sales) or \$0.85 per diluted share for fiscal year 2000.

Financial Condition, Liquidity and Capital Resources

The Company had working capital of \$198,966,000 and \$171,985,000 at June 30, 2002 and 2001, respectively. Net cash provided by operating activities was \$87,186,000 for fiscal year 2002 as compared to \$52,224,000 for fiscal year 2001

Edgar Filing: RESPIRONICS INC - Form 10-K

and \$23,620,000 for fiscal year 2000. The increase in cash flow from operating activities for all three fiscal years was primarily a result of higher earnings. Fiscal year 2002 cash flow was positively impacted by a decrease in inventory and other current asset levels compared to increases in these balances in prior years, as well as a positive impact of changes in accounts payable and accrued expenses compared to fiscal year 2001.

Net cash used by investing activities was \$44,556,000, \$27,599,000, and \$28,390,000 for fiscal years 2002, 2001, and 2000, respectively. The majority of the cash used by investing activities for all periods represented capital expenditures, including the purchase of leasehold improvements and facilities, production equipment, computer hardware and software, and telecommunications and office equipment. In addition, cash used by investing activities in all three fiscal years included additional purchase price paid for a previously acquired business pursuant to the terms of that acquisition agreement. In fiscal year 2002, cash used for investing activities also included the purchase price paid for Novamatrix and Fuji, net of cash acquired. See discussion below and Note O to the Consolidated Financial Statements for additional information about these acquisitions. Positive cash flows from operating activities and accumulated cash and cash equivalents provided funding for investment activities in all years.

Net cash provided by financing activities includes borrowings and repayments under the Company's various long-term obligations, proceeds from the issuance of common stock under the Company's stock option plans, and the acquisition and use of treasury stock.

In connection with customer leasing programs with independent leasing companies, the Company is contingently liable, in the event of a customer default, to the leasing companies within certain limits for unpaid installment receivables initiated by or transferred to the leasing companies. The transfer of certain of these installment receivables meets the criteria of Statement of Financial Accounting Standards No. 140, "Accounting for Transfers and Servicing of Financial Assets and Extinguishment of Liabilities," and therefore are not recorded on the Company's financial statements. The total exposure for unpaid installment receivables meeting these criteria and not recorded on the Company's financial statements was approximately \$18,428,000 and \$22,670,000 at June 30, 2002 and 2001, respectively. The transfer of the remainder of these installment receivables (consisting of installment receivables acquired as part of the Novamatrix acquisition) does not meet the criteria of this Standard and therefore must be recorded as collateralized borrowing arrangements. Accordingly, the Company has included \$11,826,000 of receivables sold with recourse as assets in prepaid expenses and other at June 30, 2002 and has recorded offsetting liabilities at that date in accrued expenses and other.

From August 1998 through September 1999, the Company's Board of Directors authorized several stock buybacks which represented authorization to purchase up to

4,000,000 shares of the Company's outstanding common stock. During fiscal year 2000, the Company repurchased, net of share usage, a total of 1,044,000 shares in open market transactions resulting in a net use of cash of \$9,201,000. No shares were repurchased by the Company during fiscal years 2001 or 2002. Including shares repurchased prior to fiscal year 2000, the Company has repurchased a total of 3,800,000 shares under this buyback program. At June 30, 2002, approximately 3,593,000 shares remained in treasury. Shares that are repurchased are added to treasury shares pending future use and reduce the number of shares outstanding used in calculating earnings per share.

Edgar Filing: RESPIRONICS INC - Form 10-K

In May 1998, the Company finalized a \$100,000,000 revolving credit facility with a group of commercial banks. This credit facility was initially used to refinance approximately \$55,000,000 of the Company's existing long-term debt with the remaining balance of the facility available for future borrowing. The credit facility was also used for general corporate purposes, including the stock buyback described above. The revolving credit facility permitted borrowings and repayments until its maturity in May 2003. In December 1998, the amount of the revolving credit facility was increased to \$125,000,000. The revolving credit facility was unsecured and contained certain financial covenants with which the Company must comply. The Company is currently in compliance with these covenants. The interest rate on the revolving credit facility was based on a spread over the London Interbank Borrowing Rate ("LIBOR"). During fiscal years 2002 and 2001, the Company repaid \$18,200,000 and \$20,000,000, respectively, on the revolving credit facility. As of June 30, 2002, the interest rate on amounts outstanding under the revolving credit facility was approximately 2.29%.

On August 19, 2002, the Company entered into a new Revolving Credit Agreement with a group of banks under which a total of \$150,000,000 is available with similar terms and financial covenants. The new Revolving Credit Agreement is also unsecured and matures in August 2005. See Notes D and N to the Consolidated Financial Statements for additional information about the credit facilities.

The Company has not provided a valuation allowance for deferred income tax assets because it has determined that it is more likely than not that such assets can be realized, at a minimum, through carrybacks to prior years in which taxable income was generated.

On August 1, 2002, one of the Company's significant homecare distribution customers announced that it filed a voluntary petition to reorganize under Chapter 11 of the U.S. Bankruptcy Code in order to restructure its bank debt. According to the press release issued in connection with the filing, this restructuring was announced as a "100-percent plan," meaning that creditors and vendors are expected to receive all that they are owed, either immediately or over time with interest. The press release also stated that the Company's customer elected to seek court protection in order to facilitate the restructuring of its debt while continuing to maintain normal business operations. The Company believes that based on current available information, the Company's reserve levels as of June 30, 2002, are adequate relative to its receivable with this customer. The Company will continue to monitor the situation.

Note L to the Consolidated Financial Statements summarizes the restructuring charges discussed above taken in regard to the fiscal year 2000 restructuring, including the reserve balances relating to these charges that remain at June 30, 2002. The reserves shown for employee severance, lease buyouts, and other direct expenses will require corresponding cash expenditures in future periods. The Company does not expect to incur additional charges in respect to this restructuring.

Note O to the Consolidated Financial Statements summarizes the two acquisitions that the Company made in the fourth quarter of fiscal year 2002. In the acquisition of Novamatrix, the Company issued approximately 2,400,000 shares of its common stock and issued stock options with a total value of approximately \$81 million. In the acquisition of its majority interest in Fuji, the Company paid \$6 million in cash and assumed net indebtedness of \$13 million. Total cash expended for both acquisitions, including transaction costs and net of cash acquired, was \$4.1 million.

The Company has contractual financial obligations and commercial financial commitments consisting primarily of long-term debt, capital lease

Edgar Filing: RESPIRONICS INC - Form 10-K

obligations, and non-cancelable operating leases. See Notes D, E, and N to the Consolidated Financial Statements for additional information about these obligations and commitments.

The following table summarizes significant contractual obligations and commercial commitments of the Company as of June 30, 2002:

22

CONTRACTUAL OBLIGATIONS and COMMERCIAL COMMITMENTS

Contractual Obligations	Payments Due By Period			
	Total	Less Than 1 Year	1-3 Years	4-5
Long-Term Debt	\$ 73,722,909	\$23,206,736	\$ 1,016,581	\$49,
Capital Lease Obligations	14,625,257	5,639,049	7,111,164	1,
Operating Leases	28,712,000	6,163,000	9,465,000	5,
Total Contractual Obligations	\$117,060,166	\$35,008,785	\$ 17,592,745	\$56,
	=====	=====	=====	=====

Other Commercial Commitments	Amount of Commitment Expiration Per			
	Total Amounts Committed	Less Than 1 Year	1-3 Years	4-5
Standby Letters of Credit	\$ 1,220,000	\$ 1,220,000	\$ 0	\$
	=====	=====	=====	=====

The Company believes that its sources of funding --- consisting of projected positive cash flow from operating activities, the availability of additional funds under its revolving credit facility (totaling approximately \$85,880,000 at June 30, 2002 based on the Company's August 19, 2002 Revolving Credit Agreement), and its accumulated cash and cash equivalents --- will be sufficient to meet its current and presently anticipated short-term and long-term future needs for operating activities (including payments against restructuring accruals), investing activities, and financing activities (primarily consisting of scheduled payments on long-term debt).

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

The Company is exposed to market risk from changes in interest rates and foreign exchange rates.

Interest Rates: The Company's primary interest rate risk relates to its long-term debt obligations. At June 30, 2002, the Company had total long-term

Edgar Filing: RESPIRONICS INC - Form 10-K

obligations, including the current portion of those obligations, of \$88,348,000. Of that amount, \$24,848,000 was in fixed rate obligations and \$63,500,000 was in variable rate obligations. Assuming a 10% increase in interest rates on the Company's variable rate obligations (i.e., an increase from the June 30, 2002 weighted average interest rate of 2.28% to a weighted average interest rate of 2.51%), annual interest expense would be approximately \$145,000 higher based on the June 30, 2002 outstanding balance of variable rate obligations. The Company has no interest rate swap agreements.

Foreign Exchange Rates: A substantial majority of the Company's sales, expenses, and cash flows are transacted in U.S. dollars. The Company also does business in various foreign currencies, primarily the Euro, the Japanese yen, the Hong Kong dollar and the Chinese yuan. For the year ended June 30, 2002, sales denominated in currencies other than the U.S. dollar totaled \$30,784,000, or approximately 6% of total sales. For the year ended June 30, 2002, pre-tax income denominated in currencies other than the U.S. dollar totaled \$8,742,000, or approximately 12% of total pre-tax income. An adverse change of 10% in exchange rates would have resulted in a decrease in sales of \$3,078,000 and a decrease in pre-tax income of \$874,000 for the year ended June 30, 2002. The Company's subsidiaries that operate in Germany, France, Japan, Hong Kong and China have certain accounts receivable and accounts payable denominated in U.S. dollars in addition to receivable and payable accounts in their home currencies which can act to

23

further mitigate the impact of foreign exchange rate changes. The Company has no significant foreign currency contracts.

Inflation

Inflation has not had a significant effect on the Company's business during the periods discussed.

Recent Accounting Pronouncements

In June 2001, the Financial Accounting Standards Board ("FASB") issued Statements of Financial Accounting Standards No. 141, "Business Combinations," and No. 142, "Goodwill and Other Intangible Assets," effective for fiscal years beginning after December 15, 2001. Under the new rules, goodwill and intangible assets deemed to have indefinite lives will no longer be amortized but will be subject to annual impairment tests in accordance with the Statements. Other intangible assets will continue to be amortized over their useful lives. The Company has applied the provisions of FASB No. 141 to account for business combinations consummated after July 1, 2001, including the acquisitions of Novamatrix and Fuji discussed above and in Note O to the Consolidated Financial Statements.

The Company has applied the new rules under FASB No. 142 on accounting for goodwill and other intangible assets beginning in the first quarter of fiscal year 2003. Application of the nonamortization provisions of the Statement is expected to result in an increase in annual net income of approximately \$3,000,000 or \$0.08 per diluted share. The Company has also performed the first of the required impairment tests of goodwill and indefinite lived intangible assets and no impairment has been found to exist as of July 1, 2002.

In August 2001, Statement of Financial Accounting Standards No. 143, "Accounting for Asset Retirement Obligations," was issued. This Statement requires recording the fair value of a liability for an asset retirement obligation in the period in which it is incurred, and a corresponding increase

Edgar Filing: RESPIRONICS INC - Form 10-K

in the carrying value of the related long-lived asset. Over time, the liability is accreted to its present value each period, and the capitalized cost is depreciated over the useful life of the related asset. Upon settlement of the liability, it is either settled for its recorded amount or a gain or loss upon settlement is recorded. FASB No. 143 is effective for the Company's fiscal year ending June 30, 2003. The Company believes that the impact of FASB No. 143 on its financial position and results of operations will not be material.

In August 2001, Statement of Financial Accounting Standards No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets," was issued. This Statement addresses financial accounting and reporting for the impairment or disposal of long-lived assets. This Statement supercedes FASB No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of," and the accounting and reporting provisions of Accounting Principles Board ("APB") Opinion No. 30, "Reporting the Results of Operations - Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions," for the disposal of a segment of a business (as previously defined in that Opinion). FASB No. 144 is effective for the Company's fiscal year ending June 30, 2003. The Company believes that the impact of FASB No. 144 on its financial position and results of operations will not be material.

Statement of Financial Accounting Standards No. 145, "Rescission of FASB Statements No. 4, 44, and 64, Amendment of FASB Statement No. 13, and Technical Corrections," was issued to amend FASB No. 13 and requires sale-leaseback accounting for certain lease modifications that have economic effects that are similar to sale-leaseback transactions. FASB No. 145 also makes various technical corrections to existing pronouncements that are not substantive in nature. The Company is currently evaluating the impact FASB No. 145 will have on its financial position and results of operations.

Statement of Financial Accounting Standards No. 146, "Accounting for Costs Associated with Exit or Disposal Activities," addresses financial accounting and

24

reporting for costs associated with exit or disposal activities and requires that a liability for a cost associated with an exit or disposal activity be recognized at fair value when the liability is incurred, rather than at the date of an entity's commitment to an exit plan. The provisions of FASB No. 146 are effective for exit or disposal activities that are initiated after December 31, 2002, with early application encouraged. The Company is currently evaluating the impact FASB No. 146 will have on its financial position and results of operations.

Critical Accounting Policies

The Company's Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States, which require the Company to make estimates and assumptions that may affect the reported financial condition and results of operations should actual results differ. The Company bases its estimates and assumptions on the best available information and believes them to be reasonable under the circumstances. The Company believes that of its significant accounting policies, the following may involve a higher degree of judgment and complexity.

Revenue Recognition: The Company's revenues are recognized when title to product passes to the customer, which generally occurs upon shipment to a customer location and, in the case of rental revenue and long-term service

Edgar Filing: RESPIRONICS INC - Form 10-K

contracts, is recognized ratably over the period the product is rented or services are performed. From time to time, the Company offers favorable sales arrangements to certain of its largest customers in exchange for volume purchase commitments. These customers make such large purchases for a variety of reasons, including the desire to reduce shipping costs and to correspond to their own budgeting and purchasing cycles. The Securities and Exchange Commission's Staff Accounting Bulletin ("SAB") No. 101, "Revenue Recognition," provides guidance on the application of generally accepted accounting principles to selected revenue recognition issues. The Company has concluded that its revenue recognition policy is appropriate and in accordance with generally accepted accounting principles and SAB No. 101.

Allowance for Uncollectible Accounts Receivable: Accounts receivable are reduced by an allowance for amounts that may become uncollectible in the future. Substantially all of the Company's receivables are due from health care product providers, distributors, and hospitals. The Company's customers are located throughout the United States and around the world. A significant portion of products sold to providers, distributors, and hospitals, both foreign and domestic, is ultimately funded through government reimbursement programs or through private insurance programs. As a consequence, changes in these programs can have an adverse impact on distributor and hospital liquidity and profitability. In addition, because a concentration of market share exists in the homecare product industry in the United States among national and large regional providers, the Company experiences a comparable concentration of credit risk with these customers. The estimated allowance for uncollectible amounts is based primarily on the Company's evaluation of the payment pattern and financial condition of its customers. In addition, the Company is contingently liable, within certain limits, in the event of a customer default on unpaid installment receivables initiated by or transferred to several independent leasing companies in connection with customer leasing programs. The Company monitors the collection status of these installment receivables and provides amounts necessary for estimated losses in the allowance for doubtful accounts.

Inventories and Related Allowance for Obsolete and Excess Inventory: Inventories are valued at the lower of cost or market value and have been reduced by an allowance for excess and obsolete inventories. The estimated allowance is based on the Company's review of inventories on hand compared to estimated future usage and sales. If it is determined that inventory on hand is in excess of estimated future usage and sales because of product obsolescence, changes in customer demand, or other reasons, additional inventory reserves may need to be provided. The establishment of these additional reserves may have an adverse impact on earnings, depending on the extent and amount of inventory affected.

Intangible and Product Technology Related Assets: Intangible and product technology related assets are amortized to expense over their useful lives. These

useful lives are based on the Company's estimates of the period that the assets will generate revenue. Intangible and product technology related assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such asset may not be recoverable. If such carrying amounts are determined to be unrecoverable because of changes in technology, extended delays in obtaining regulatory approval, competition, or other reasons, the carrying amounts may need to be adjusted. These adjustments may have an adverse impact on earnings, depending on the significance of the carrying amounts and the extent of the required adjustments.

Edgar Filing: RESPIRONICS INC - Form 10-K

Contingencies: As a normal part of its business operations, the Company incurs liabilities that may be difficult to quantify precisely, such as future warranty obligations, potential liabilities relating to legal or regulatory matters, and tax exposures. The Company follows the requirements of Statement of Financial Accounting Standards No. 5, "Accounting for Contingencies," which dictate when a charge to income should be taken to accrue for a loss contingency. These requirements necessitate the application of judgment regarding the likelihood and amount of the liability.

CAUTIONARY STATEMENT FOR PURPOSES OF THE "SAFE HARBOR" PROVISIONS OF THE PRIVATE SECURITIES REFORM ACT OF 1995.

The statements contained in this Annual Report, including those contained in "Management's Discussion and Analysis of Results of Operations and Financial Condition," along with statements in reports filed with the Securities and Exchange Commission, external documents and oral presentations which are not historical are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21B of the Securities Exchange Act of 1934, as amended. These forward-looking statements represent the Company's present expectations or beliefs concerning future events. The Company cautions that such statements are qualified by important factors that could cause actual results to differ materially from the expected results included in the forward-looking statements. Those factors include, but are not limited to, the following: foreign currency fluctuations, regulations and other factors affecting operations and sales outside the United States including potential future effects of the change in sovereignty of Hong Kong, customer consolidation and concentration, increasing price competition and other competitive factors in the sale of products, the success of the Company's marketing, sales, and promotion programs, interest rate fluctuations, intellectual property and related litigation, other litigation, successful integration of acquisitions, FDA and other government regulation, anticipated levels of earnings and revenues, and third party reimbursement.

Item 8. Consolidated Financial Statements

Index to Consolidated Financial Statements	
Report of Independent Auditors	27
Consolidated Balance Sheets as of June 30, 2002 and 2001	28
Consolidated Statements of Operations for the years ended June 30, 2002, 2001, and 2000	29
Consolidated Statements of Cash Flows for the years ended June 30, 2002, 2001, and 2000	30
Consolidated Statements of Shareholders' Equity for the years ended June 30, 2002, 2001, and 2000	31
Notes to Consolidated Financial Statements	32

Edgar Filing: RESPIRONICS INC - Form 10-K

Board of Directors
Respironics, Inc. and Subsidiaries

We have audited the accompanying consolidated balance sheets of Respironics, Inc. and Subsidiaries as of June 30, 2002 and 2001, and the related consolidated statements of operations, shareholders' equity, and cash flows for each of the three years in the period ended June 30, 2002. Our audits also included the financial statement schedule listed in the Index at Item 14(a). These financial statements and schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements and schedule based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Respironics, Inc. and Subsidiaries at June 30, 2002 and 2001, and the consolidated results of their operations and their cash flows for each of the three years in the period ended June 30, 2002, in conformity with accounting principles generally accepted in the United States. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

/s/Ernst & Young LLP

Pittsburgh, Pennsylvania
July 23, 2002, except for Note N as
to which the date is August 19, 2002

27

CONSOLIDATED BALANCE SHEETS

RESPIRONICS, INC. AND SUBSIDIARIES

At June 30

2002

ASSETS

CURRENT ASSETS

Cash and cash equivalents	\$	62,334,684	\$
Trade accounts receivable, less allowance for doubtful accounts of \$18,458,000 and \$16,457,000		121,281,073	
Inventories		86,632,027	
Prepaid expenses and other		23,875,193	
Deferred income tax benefits		15,728,389	

TOTAL CURRENT ASSETS

309,851,366

Edgar Filing: RESPIRONICS INC - Form 10-K

PROPERTY, PLANT AND EQUIPMENT		
Land		2,867,555
Building		16,777,382
Machinery and equipment		133,872,197
Furniture, office and computer equipment		67,768,498
Leasehold improvements		6,413,872

		227,699,504
Less allowances for depreciation and amortization		127,764,645

		99,934,859
OTHER ASSETS		33,802,545
GOODWILL		103,860,749

	\$	547,449,519
		=====
LIABILITIES AND SHAREHOLDERS' EQUITY		
CURRENT LIABILITIES		
Accounts payable	\$	39,081,748
Accrued expenses and other		42,958,007
Current portion of long-term obligations		28,845,785

TOTAL CURRENT LIABILITIES		110,885,540
LONG-TERM OBLIGATIONS		59,502,381
MINORITY INTEREST and OTHER		9,341,531
SHAREHOLDERS' EQUITY		
Common Stock, \$.01 par value; authorized 100,000,000 shares; issued and outstanding 36,885,795 shares at June 30, 2002 and 34,013,785 shares at June 30, 2001		368,858
Additional capital		213,837,023
Accumulated other comprehensive loss		(2,718,213)
Retained earnings		198,450,389
Treasury stock		(42,217,990)

TOTAL SHAREHOLDERS' EQUITY		367,720,067

	\$	547,449,519
		=====

See notes to consolidated financial statements.

Edgar Filing: RESPIRONICS INC - Form 10-K

RESPIRONICS, INC. AND SUBSIDIARIES

Year Ended June 30	2002	2001
	-----	-----
Net sales	\$ 494,918,654	\$ 422,118,000
Cost of goods sold	260,795,012	223,118,000
Cost of goods sold - restructuring charges	0	0
	-----	-----
	234,123,642	198,118,000
General and administrative expenses	60,718,793	50,118,000
Sales, marketing and commission expenses	86,188,885	72,118,000
Research and development expenses	17,317,462	15,118,000
Integration and restructuring charges (credit)	2,288,398	(1,118,000)
Impairment charge	2,005,722	0
Interest expense	3,011,018	7,118,000
Other income	(1,442,853)	(1,118,000)
	-----	-----
	170,087,425	142,118,000
	-----	-----
INCOME BEFORE INCOME TAXES	64,036,217	55,118,000
Income taxes	25,619,349	22,118,000
	-----	-----
NET INCOME	\$ 38,416,868	\$ 33,118,000
	=====	=====
Basic earnings per share	\$ 1.24	\$ 1.24
	=====	=====
Basic shares outstanding	31,079,282	29,118,000
Diluted earnings per share	\$ 1.20	\$ 1.20
	=====	=====
Diluted shares outstanding	32,008,359	30,118,000

See notes to consolidated financial statements.

29

CONSOLIDATED STATEMENTS OF CASH FLOWS

RESPIRONICS, INC. AND SUBSIDIARIES

Year Ended June 30	2002	2001
	-----	-----
OPERATING ACTIVITIES		
Net income	\$ 38,416,868	\$ 33,118,000
Adjustments to reconcile net income to net cash provided by operating activities:		

Edgar Filing: RESPIRONICS INC - Form 10-K

Depreciation	28,578,753
Amortization	5,653,328
Tax benefit from exercise of stock options	2,766,453
Provision for asset write-offs	2,005,722
Gain on sale of property, plant, and equipment	0
Provision for bad debts	3,275,000
Provision (benefit) for deferred income taxes	3,251,495
Changes in operating assets and liabilities:	
Increase in accounts receivable	(7,905,452)
Decrease (increase) in inventories and other current assets	9,052,239
Increase in other assets	(3,637,616)
Increase (decrease) in accounts payable and accrued expenses	5,728,845

NET CASH PROVIDED BY OPERATING ACTIVITIES	87,185,635
INVESTING ACTIVITIES	
Purchase of property, plant and equipment	(39,829,553)
Proceeds from sale of property, plant, and equipment	0
Acquisition of businesses, net of cash acquired	(4,726,200)

NET CASH USED BY INVESTING ACTIVITIES	(44,555,753)
FINANCING ACTIVITIES	
Proceeds from long-term obligations	4,531,085
Reduction in long-term obligations	(21,198,203)
Issuance of common stock	8,382,625
Use (acquisition) of treasury stock, net	370,377
Increase (decrease) in minority interest and other	298,008

NET CASH (USED) PROVIDED BY FINANCING ACTIVITIES	(7,616,108)

INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	35,013,774
Cash and cash equivalents at beginning of period	27,320,910

CASH AND CASH EQUIVALENTS AT END OF PERIOD	\$ 62,334,684
	=====

See notes to consolidated financial statements.

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
RESPIRONICS, INC. AND SUBSIDIARIES

Common Stock

Accumulated

Edgar Filing: RESPIRONICS INC - Form 10-K

	Shares	Amount	Additional Capital	Comprehensive Income (Loss)	Retained Earnings
BALANCE AT JUNE 30, 1999	32,999,332	\$329,993	\$108,863,191	\$(1,231,013)	\$120,709,953
Shares sold pursuant to stock option plans	183,233	1,833	1,518,105	0	0
Net acquisition and use of treasury stock	0	0	0	0	0
Income tax benefit from exercise of stock options	0	0	414,354	0	0
Comprehensive income (loss):					
Net income for the year ended June 30, 2000	0	0	0	0	5,752,284
Foreign currency translation adjustments	0	0	0	(1,900,690)	0
Total comprehensive income (loss)	0	0	0	(1,900,690)	5,752,284
BALANCE AT JUNE 30, 2000	33,182,565	331,826	110,795,650	(3,131,703)	126,462,237
Shares sold pursuant to stock option and purchase plans	831,220	8,312	7,777,144	0	0
Income tax benefit from exercise of stock options	0	0	3,147,495	0	0
Comprehensive income (loss):					
Net income for the year ended June 30, 2001	0	0	0	0	33,571,284
Foreign currency translation adjustments	0	0	0	(1,105,730)	0
Total comprehensive income (loss)	0	0	0	(1,105,730)	33,571,284
BALANCE AT JUNE 30, 2001	34,013,785	340,138	121,720,289	(4,237,433)	160,033,521
Shares sold pursuant to stock option and purchase plans	472,617	4,726	8,377,899	0	0
Net acquisition and use of treasury stock	0	0	0	0	0
Income tax benefit from exercise of stock options	0	0	2,766,453	0	0
Stock issued for business acquired	2,399,393	23,994	80,972,382	0	0
Comprehensive income:					
Net income for the year ended June 30, 2002	0	0	0	0	38,416,868

Edgar Filing: RESPIRONICS INC - Form 10-K

Foreign currency translation adjustments	0	0	0	1,519,220	0
Total comprehensive income	0	0	0	1,519,220	38,416,868
BALANCE AT JUNE 30, 2002	36,885,795	\$368,858	\$213,837,023	\$(2,718,213)	\$198,450,389

See notes to consolidated financial statements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

RESPIRONICS, INC. AND SUBSIDIARIES

NOTE A -- SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation:

The consolidated financial statements include the accounts of Respironics, Inc. (the "Company") and its wholly and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Minority interests in majority owned subsidiaries have been recorded.

Revenue Recognition:

Revenue is recognized from sales when title to product passes to the customer, which generally occurs upon shipment to a customer location. Rental and service revenues are recognized when billed on a monthly basis consistent with the rental and service periods.

Shipping and Handling Costs:

Shipping and handling costs are expensed as incurred and are included in cost of goods sold.

Inventories:

Inventories are valued at the lower of cost (first-in, first-out) or market.

Property, Plant and Equipment:

Property, plant and equipment is recorded on the basis of cost. Costs incurred to purchase or develop software for internal use, including upgrades and enhancements, are capitalized during the software application development stage in accordance with Statement of Position No. 98-1, "Accounting for the Costs of Computer Software Developed or Obtained for Internal Use." Depreciation is computed using the straight-line method based upon the estimated useful lives of the respective assets, which are 30 years for buildings and generally range from two to five years for other property, plant, and equipment. Amortization of assets under capital leases is included in depreciation expense.

Income Taxes:

Provisions for income taxes include deferred taxes resulting from temporary differences in income for financial and tax purposes using the liability method.

Edgar Filing: RESPIRONICS INC - Form 10-K

Such temporary differences result primarily from differences in the carrying value of assets and liabilities.

The Company does not provide for federal income taxes on the undistributed earnings of its foreign subsidiaries (other than deemed dividends which are taxed currently) because such earnings are reinvested and, in the opinion of management, will continue to be reinvested indefinitely.

Foreign Currency Translation:

Foreign currency assets and liabilities are translated into U.S. dollars at the rate of exchange existing at the statement date or historical rates depending upon the nature of the account. Income and expense amounts are translated at the average of the monthly exchange rates. Adjustments resulting from these translations are credited or charged directly to accumulated comprehensive income (loss). Gains and losses resulting from foreign currency transactions are credited or charged directly to income.

Stock Options:

Stock options are granted to certain employees and certain members of the Company's Board of Directors at the fair market value of the Company's stock on the date of the grant. Proceeds from the exercise of common stock options are credited to shareholders'

32

equity at the date the options are exercised. There are no charges or credits to income with respect to these options. The Company follows the requirements of Accounting Principles Board ("APB") Opinion No. 25, "Accounting for Stock Issued to Employees," as amended, in accounting for stock-based compensation.

Earnings per Share:

Basic earnings per share are based on the weighted average number of shares actually outstanding. Diluted earnings per share are based on the weighted average number of shares actually outstanding and dilutive potential shares, such as dilutive stock options and warrants which are determined using the treasury stock method.

Cash and Cash Equivalents:

The Company considers all highly liquid investments with a maturity of 30 days or less when purchased to be cash and cash equivalents.

Capitalized Software Production Costs:

Software development costs have been capitalized when technological feasibility was established and are being amortized to the cost of product revenues over the estimated economic lives (generally three to five years) of the products that include such software. Total net capitalized software production costs were \$4,515,000 and \$1,940,000 at June 30, 2002 and 2001, respectively.

Advertising Costs:

Advertising is charged to expenses during the period in which it is incurred. Total advertising expenses for the fiscal years ended June 30, 2002, 2001, and 2000 were \$965,000, \$805,000, and \$1,224,000, respectively.

Goodwill and Other Long-Lived Assets:

Goodwill is the cost in excess of the fair value of net assets of businesses acquired and is amortized on the straight-line method over periods from 15 to 40 years. Accumulated amortization was \$23,099,000 and \$19,289,000 at June 30, 2002 and 2001, respectively. Through fiscal year 2002, the Company has evaluated the carrying value of goodwill and other long-lived assets for potential impairment on an ongoing basis. Such evaluation considers projected future operating results, trends and other circumstances. If factors indicated that goodwill or other long-lived assets could be impaired, the Company would use an estimate of the related undiscounted future cash flows over the remaining life of the goodwill or other long-lived asset in measuring whether the goodwill or other long-lived asset is recoverable. If such an analysis indicated that impairment had occurred, the Company would adjust the book value of the goodwill or other long-lived asset to fair value.

In June 2001, the Financial Accounting Standards Board ("FASB") issued Statement No. 141, "Business Combinations," and Statement No. 142, "Goodwill and Other Intangible Assets," effective for fiscal years beginning after December 15, 2001. Under the new rules, goodwill and intangible assets deemed to have indefinite lives will no longer be amortized but will be subject to annual impairment tests in accordance with the Statements. Other intangible assets will continue to be amortized over their useful lives. The Company has applied the provisions of FASB No. 141 to account for business combinations consummated after July 1, 2001, including the acquisitions of Novamatrix Medical Systems Inc. ("Novamatrix") and Fuji, RC Co., Ltd. ("Fuji") discussed in Note O to these Consolidated Financial Statements.

Effective July 1, 2002, the Company has adopted Statement of Financial Accounting Standards No. 142, "Goodwill and Other Intangible Assets," under which goodwill and intangible assets deemed to have indefinite lives will no longer be amortized but will be subject to annual impairment tests. The Company has performed the first of its required impairment tests with the adoption of FASB No. 142 and has determined that no impairment exists as of July 1, 2002. Application of the nonamortization provisions of the Statement is expected to result in an increase in annual net income of approximately \$3,000,000 or \$0.08 per diluted share.

33

Accrued Expenses and Other:

Accrued expenses and other includes accrued compensation of \$11,060,000 and \$6,887,000 at June 30, 2002 and 2001, respectively.

Comprehensive Income:

Comprehensive income consists of net income and foreign currency translation adjustments and is presented in the Consolidated Statements of Shareholders' Equity.

Recent Accounting Pronouncements:

In August 2001, the FASB issued Statement No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets." This Statement addresses financial accounting and reporting for the impairment or disposal of long-lived assets. This Statement supercedes FASB No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of," and the accounting and reporting provisions of Accounting Principles Board ("APB") Opinion No. 30, "Reporting the Results of Operations - Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently

Edgar Filing: RESPIRONICS INC - Form 10-K

Occurring Events and Transactions," for the disposal of a segment of a business (as previously defined in that Opinion). FASB No. 144 is effective for the Company's fiscal year ending June 30, 2003. The Company believes that the impact of FASB No. 144 on its financial position and results of operations will not be material.

Statement of Financial Accounting Standards No. 146, "Accounting for Costs Associated with Exit or Disposal Activities," addresses financial accounting and reporting for costs associated with exit or disposal activities and requires that a liability for a cost associated with an exit or disposal activity be recognized at fair value when the liability is incurred, rather than at the date of an entity's commitment to an exit plan. The provisions of FASB No. 146 are effective for exit or disposal activities that are initiated after December 31, 2002, with early application encouraged. The Company is currently evaluating the impact FASB No. 146 will have on its financial position and results of operations.

Use of Estimates:

 The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Changes in Presentation of Comparative Financial Statements:

 Certain amounts in the June 30, 2001 and 2000 financial statements were reclassified to conform with the presentation in the current period.

NOTE B - CASH EQUIVALENTS

Cash equivalents consist primarily of money market accounts and certificates of deposit issued by large commercial banks located in the United States and Hong Kong.

34

NOTE C -- INVENTORIES

Inventories consisted of the following:

	June 30	
	2002	2001
Raw materials	\$15,236,332	\$20,738,160
Work-in-process	8,135,768	5,960,618
Finished goods	63,259,927	46,719,118
	\$86,632,027	\$73,417,896

NOTE D - LONG-TERM OBLIGATIONS

Long-term obligations consisted of the following:

Edgar Filing: RESPIRONICS INC - Form 10-K

	June 30	
	2002	2001
	-----	-----
Commercial Bank Credit Agreement, payable in one lump sum in August 2005 including interest at a floating rate (2.29% at June 30, 2002); see Note N	\$62,900,000	\$81,100,000
Bank Debt with varying maturities (final maturity in September 2005) including interest rates ranging from 0.833% to 2.25%	8,675,928	0
Capital Lease Obligations, payable in monthly installments with varying completion dates through April 2007 including interest rates ranging from 2.9% to 3.0%	14,625,257	0
Other	2,146,981	2,953,695
	-----	-----
	88,348,166	84,053,695
Less current portion	28,845,785	3,998,317
	-----	-----
	\$59,502,381	\$80,055,378
	=====	=====

Other long-term obligations in the above table includes an Economic Development Revenue Bond, Industrial Development Authority Loans, and a Redevelopment Authority Loan that are secured by mortgages on the Company's manufacturing facility in Murrysville, Pennsylvania. Proceeds from the bonds and the loans were used to finance the construction and expansion of some of the Company's facilities. The Capital Lease Obligations are primarily for ventilators and other equipment rented to outside customers by the Company's Fuji subsidiary. The Commercial Bank Credit Agreement, under which a total of \$125,000,000 was available, was unsecured. The Company was required to meet certain financial covenants in connection with these obligations, including those relating to current ratio, ratio of total liabilities to tangible net worth, minimum tangible net worth, leverage, and interest coverage. At June 30, 2002, the Company was in compliance with these covenants. The Commercial Bank Revolving Credit Agreement included a commitment fee, currently equal to 0.150%, on the unused portion of the facility.

35

Scheduled maturities of long-term obligations for the next five years are as follows:

	Maturities of Long-Term Debt

2003	\$28,845,785
2004	4,910,823
2005	3,216,922
2006	50,497,208

Edgar Filing: RESPIRONICS INC - Form 10-K

2007	641,049
Thereafter	236,379

TOTAL	\$88,348,166
	=====

Interest paid was \$2,983,000, \$7,870,000, and \$6,590,000, for the years ended June 30, 2002, 2001, and 2000, respectively.

NOTE E - OPERATING LEASES

The Company leases its service centers, its central distribution center, and certain of its offices, warehouses and manufacturing facilities in the United States and also leases its offices, warehouses and manufacturing facilities in the Far East and in Europe.

The minimum rentals due under noncancelable leases with recurring terms of one year or more as of June 30, 2002 are as follows:

Year Ending June 30	Amount
-----	-----
2003	\$ 6,163,000
2004	5,265,000
2005	4,200,000
2006	3,183,000
2007	2,664,000
Thereafter	7,237,000

TOTAL	\$28,712,000
	=====

Total rent expense for the years ended June 30, 2002, 2001, and 2000, was \$5,255,000, \$4,605,000, and \$3,841,000, respectively.

NOTE F -- FAIR VALUE OF FINANCIAL INSTRUMENTS

The following methods and assumptions were used to estimate the fair value of financial instruments:

CASH AND CASH EQUIVALENTS

The carrying amount approximates fair value because of the short maturity of those investments.

LONG-TERM OBLIGATIONS

The fair values of long-term debt obligations are established from the market values of similar issues. The carrying amounts of the Company's obligations approximate their fair values at June 30, 2002 and 2001.

NOTE G -- INCOME TAXES

Income (loss) before income taxes consisted of the following:

Edgar Filing: RESPIRONICS INC - Form 10-K

	Year Ended June 30		
	2002	2001	2000
	-----	-----	-----
United States	\$55,870,449	\$56,058,248	\$ 10,020,446
Foreign	8,165,768	(150,204)	(1,444,563)
	-----	-----	-----
TOTAL	\$64,036,217	\$55,908,044	\$ 8,575,883
	=====	=====	=====

Income taxes (benefit) consisted of:

	Year Ended June 30		
	2002	2001	2000
	-----	-----	-----
Current:			
Federal	\$16,873,746	\$17,157,270	\$ 5,975,847
Foreign	1,617,787	(595,422)	184,800
State	3,876,321	2,825,817	1,078,628
Tax benefit from exercise of stock options	(2,766,453)	(3,147,495)	(414,354)
	-----	-----	-----
	19,601,401	16,240,170	6,824,921
Deferred:			
Federal	2,921,678	2,579,968	(3,775,687)
State	329,817	369,127	(639,989)
	-----	-----	-----
	3,251,495	2,949,095	(4,415,676)
Credit to additional paid-in- capital for tax benefit from stock option exercises	2,766,453	3,147,495	414,354
	-----	-----	-----
TOTAL INCOME TAXES	\$25,619,349	\$22,336,760	\$ 2,823,599
	=====	=====	=====

The difference between the statutory U.S. federal income tax rate and the Company's effective income tax rate is explained below:

	Year Ended June 30		
	2002	2001	2000
	-----	-----	-----
Statutory federal income tax rate	35%	35%	35%
Increases (decreases):			
State taxes, net of federal benefit	4	4	3
Foreign taxes	(2)	0	7
Tax credits	(1)	(1)	(8)
Tax liability adjustment	0	0	(19)

Edgar Filing: RESPIRONICS INC - Form 10-K

Non-deductible expenses (primarily goodwill amortization)	3	1	14
Other items, net	1	1	1
	----	----	----
 EFFECTIVE INCOME TAX RATE	 40%	 40%	 33%
	=====	=====	=====

37

Deferred income tax assets consisted of the following:

	June 30	
	2002	2001
	-----	-----
Allowance for bad debts	\$ 6,796,484	\$ 5,849,756
Depreciation	(1,071,411)	(987,067)
Inventory reserves	3,497,260	4,663,616
Restructuring reserves	1,096,489	840,349
Net operating loss carryforward, limited by Section 382	1,724,127	0
Business credits carryforward, limited by Section 383	711,870	0
Other	2,973,570	3,835,297
	-----	-----
TOTAL	\$15,728,389	\$14,201,951
	=====	=====

Undistributed earnings of the foreign subsidiaries on which no U.S. income tax has been provided amounted to \$12,932,775 at June 30, 2002.

Income taxes paid were \$19,170,284, \$19,533,062, and \$3,286,051, for the years ended June 30, 2002, 2001, and 2000, respectively.

On April 12, 2002, the Company acquired Novamatrix Medical Systems Inc. which had a federal and state net operating loss for the period ending April 12, 2002 of approximately \$5,800,000. Such net operating loss on a carryforward basis expires in 2022. Additionally, Novamatrix had unused research tax credits of approximately \$475,000 which expire in varying amounts through 2013 and alternative minimum tax credits of \$237,000 which do not have expiration dates. As a result of the ownership change, the utilization of the net operating loss and the credit carryforwards is limited each year by Internal Revenue Code Sections 382 and 383, respectively. The Company expects to fully utilize the net operating loss and credit carryforwards.

The change in deferred income tax assets between June 30, 2001 and June 30, 2002 includes \$4,777,933 resulting from acquisitions.

During fiscal year 2000, the Company reached an agreement with the Internal Revenue Service regarding examinations of federal income tax returns for certain of the Company's U.S. entities for fiscal years 1996 through 1998. Based on this agreement, the Company recorded a one-time reduction in income tax liability and income tax expense of \$1,643,000 during that year.

NOTE H -- STOCK OPTION AND PURCHASE PLANS

Edgar Filing: RESPIRONICS INC - Form 10-K

The Company has in place the 1984 Incentive Stock Option Plan (the "1984 Plan"), the 1992 Stock Incentive Plan (the "1992 Plan") and the 2000 Stock Incentive Plan (the "2000 Plan"), which provide options to eligible employees, and in the case of the 2000 Plan, to eligible consultants and non-employee directors (as described below in the case of non-employee directors), to purchase common stock for a period up to ten years at option prices not less than fair market value at the time of the grant. Under the 1984 and 1992 Plans, options become exercisable no sooner than six months from the date of the grant at rates that vary depending on the plan and are subject to possible acceleration in certain circumstances. Under the 2000 Plan, options become exercisable at such times or upon the occurrence of such events as determined by the Committee administering the 2000 Plan. Under the 1992 and 2000 Plans, options may include cash payment rights and restricted shares of the Company's common stock may also be awarded. The 1984 Plan, which terminated as to new grants in 1993, had 3,400,000 shares approved for issuance. The 1992 Plan has a total of 3,000,000 shares approved for issuance, including 1,000,000 options that were approved by the Company's shareholders when the 1992 Plan was adopted and an additional 2,000,000 shares that were approved by the Company's shareholders in November 1998. The 2000 Plan has a total of 1,400,000 shares approved for issuance.

The Company also has in place the 1991 Non-Employee Directors' Stock Option Plan (the "Directors' Plan"), the shares available under which were exhausted in 2001. The 2000 Plan replaced the Directors' Plan for current grants. Options previously granted under

38

the Directors' Plan, and currently granted under the 2000 Plan, are granted to members of the Company's Board of Directors who are not employees of the Company. Each non-employee director receives an option to purchase 5,100 shares on the third business day following the Company's annual meeting of shareholders. These grants will continue until options for all the shares available under the 2000 Plan have been granted. Such options are granted at fair market value on the date of grant. For options granted to non-employee directors, 25% of the shares are exercisable one year after the date of the grant, 25% are exercisable two years after the date of grant, and the remaining 50% are exercisable three years after the date of grant. All options granted under the Directors' Plan and the 2000 Plan expire ten years after the date of grant. The Directors' Plan had 300,000 options approved for issuance, which were exhausted in 2001.

Healthdyne had in place, prior to its merger with the Company, four stock option plans: the 1993 Stock Option Plan; the 1993 Nonemployee Director Stock Option Plan; the 1995 Stock Option Plan II; and the 1996 Stock Option Plan. At the date of the merger, the outstanding Healthdyne options were converted into a total of 1,360,061 options to purchase Respiroics common stock. Under the terms of the Healthdyne plans, all such options became immediately exercisable at the date of the merger and the plans terminated as to new grants. All future stock option grants will be made from Respiroics stock option plans.

Novamatrix had in place, prior to its merger with the Company, five stock option plans: the 1990 Stock Option Plan; the 1994 Stock Option Plan; the 1997 Long Term Incentive Plan; the 1999 Incentive Plan; and the 2000 Long Term Incentive Plan. Novamatrix also had in place certain stock option agreements, separately from its plans, with its President and its Chief Operating Officer. At the date of the merger, the outstanding Novamatrix options were converted into a total of 416,125 options to purchase Respiroics common stock. Under the terms of the Novamatrix plans and agreements, all such options become immediately exercisable in connection with the merger and the plans terminated as to new grants. All

Edgar Filing: RESPIRONICS INC - Form 10-K

future stock option grants will be made from Respironics stock option plans.

Pertinent information regarding options under all Plans is as follows:

	Option Shares		

	Year Ended June 30		
	2002	2001	2000
	-----	-----	-----
Outstanding at beginning of period	2,173,989	2,584,479	1,950,861
Granted:			
Price range (\$10.33 - \$33.75)	1,180,959		
Price range (\$16.13 - \$29.93)		604,000	
Price range (\$ 7.94 - \$14.44)			1,092,247
Exercised:			
Price range (\$ 6.22 - \$26.19)	(486,225)		
Price range (\$ 4.50 - \$24.63)		(833,840)	
Price range (\$ 2.81 - \$16.25)			(183,233)
Canceled	(104,695)	(180,650)	(275,396)
	-----	-----	-----
Outstanding at end of period (Weighted average price \$19.69)	2,764,028	2,173,989	2,584,479
	=====	=====	=====
Exercisable at end of period	1,104,509	647,692	1,100,821
	=====	=====	=====
Shares available for future grant	1,648,722	2,308,861	1,332,211
	=====	=====	=====

39

The range of grant and exercise prices above includes the post-conversion option prices for options granted by Novamatrix prior to its merger with the Company.

The per share weighted-average fair value of stock options granted during 2002, 2001, and 2000, was \$17.35, \$10.39, and \$4.81, respectively, on the date of grant using the Black-Scholes option-pricing model with the following assumptions:

	2002	2001	2000
	-----	-----	-----
Expected volatility	53.0%	57.1%	56.8%
Expected dividend yield	none	none	none
Risk-free interest rate	4.1%	5.0%	6.0%
Expected life of stock options	5	5	5

Edgar Filing: RESPIRONICS INC - Form 10-K

The Company applies APB Opinion No. 25, as amended, in accounting for its stock option plans and accordingly, no compensation cost has been recognized for its stock options in the financial statements. Had the Company determined compensation cost based on the fair value at the grant date for its stock options under Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based Compensation," the Company's net earnings and related per share amounts would have been reduced to the pro forma amounts indicated below:

	2002 -----	2001 -----	2000 -----
Net earnings:			
As reported	\$38,416,868	\$33,571,284	\$ 5,752,284
Pro forma	33,311,365	30,202,284	3,365,284
Diluted earnings per share:			
As reported	1.20	1.09	0.19
Pro forma	1.04	0.98	0.11

Novamatrix also had in place, prior to its merger with the Company, warrants outstanding to purchase shares of its common stock. At the date of the merger, the outstanding Novamatrix warrants were converted into a total of 91,013 warrants to purchase Respironics common stock with exercise prices ranging from \$10.33 per share to \$29.52 per share. The warrants expire at various dates through March 2005 and are all currently exercisable.

In March 1997, the Company adopted the 1997 Employee Stock Purchase Plan (the "1997 Plan") under which employees could purchase common stock of the Company through payroll deductions during each Plan year beginning in 1997 through 2001. The 1997 Plan terminated as to future grants after 2001. In August 2001, the Company adopted the 2002 Employee Stock Purchase Plan (the "2002 Plan") under which employees can purchase common stock of the Company through payroll deductions during each Plan year beginning in 2002 through 2006. The purchase price under each Plan is the lesser of 85% of the market value of the Company's common stock on either the first or last day of the Plan year. The maximum amount each employee can purchase currently under the 2002 Plan, and historically could purchase under the 1997 Plan, is equal to 20% of annual compensation. There are no charges or credits to income in connection with the Plans. Shares are purchased at the end of each Plan year with the funds set aside through payroll deductions.

In June 1996, the Company adopted a shareholders' rights plan under which existing and future shareholders received a right for each share outstanding entitling such shareholders to purchase shares of the Company's common stock at a specified exercise price. The right to purchase such shares is not currently exercisable, but would become exercisable in the future if certain events occurred relating to a person or group (the "acquiror") acquiring or attempting to acquire 20% or more of the Company's outstanding shares of common stock. In the event the rights become exercisable, each right would entitle the holder (other than the acquiror) to purchase shares of the Company's common stock having a value equal to two times the specified exercise price.

40

NOTE I - INDUSTRY SEGMENT, FINANCIAL INFORMATION BY GEOGRAPHIC AREAS AND MAJOR CUSTOMERS

The Company conducts its operations in one reportable industry segment; the

Edgar Filing: RESPIRONICS INC - Form 10-K

design, development, manufacture and sale of medical devices. Sales by product within this segment are as follows:

	Year Ended June 30		
	2002	2001	2000
	-----	-----	-----
NET SALES			
Homecare	\$410,796,354	\$357,223,198	\$307,644,676
Hospital	60,813,140	43,235,211	38,595,151
Asthma and Allergy	23,309,160	21,979,453	21,944,283
	-----	-----	-----
NET SALES	\$494,918,654	\$422,437,862	\$368,184,110
	=====	=====	=====

Financial information about the Company by geographic area is presented below. The term "Foreign" is used to describe the Company's operations in Hong Kong, Germany, China, Japan, and France.

	Year Ended June 30		
	2002	2001	2000
	-----	-----	-----
NET SALES			
United States:			
Unaffiliated customers	\$458,470,999	\$400,361,214	\$342,454,391
Interarea transfers	21,176,011	17,644,344	81,490,976
	-----	-----	-----
	479,647,010	418,005,558	423,945,367
Foreign:			
Unaffiliated customers	36,447,655	22,076,648	25,729,719
Interarea transfers	15,223,575	9,882,463	8,071,010
	-----	-----	-----
	51,671,230	31,959,111	33,800,729
Elimination--Transfers	36,399,586	27,526,807	89,561,986
	-----	-----	-----
NET SALES	\$494,918,654	\$422,437,862	\$368,184,110
	=====	=====	=====
OPERATING PROFIT			
United States	\$ 73,762,027	\$ 72,736,494	\$ 53,214,768
Foreign	9,555,227	1,124,102	2,435,236
	-----	-----	-----
OPERATING PROFIT	83,317,254	73,860,596	55,650,004
Corporate expense, including non-recurring items	16,270,019	10,407,017	40,128,536
Interest expense	3,011,018	7,545,535	6,945,585
	-----	-----	-----
INCOME BEFORE INCOME TAXES	\$ 64,036,217	\$ 55,908,044	\$ 8,575,883
	=====	=====	=====

Interarea transfers are accounted for at prices comparable to unaffiliated customer sales reduced by an approximation of costs not incurred on internal

Edgar Filing: RESPIRONICS INC - Form 10-K

sales.

Additional information regarding assets and liabilities by geographic area follows:

41

	June 30	
	2002	2001
	-----	-----
IDENTIFIABLE ASSETS		
United States	\$401,844,394	\$303,913,079
Foreign	67,542,052	21,859,167
	-----	-----
	469,386,446	325,772,246
Corporate assets (cash and cash equivalents and deferred income taxes)	78,063,073	41,522,861
	-----	-----
TOTAL ASSETS	\$547,449,519	\$367,295,107
	=====	=====
TOTAL ASSETS		
United States	\$463,359,111	\$339,291,183
Foreign	84,090,408	28,003,924
	-----	-----
TOTAL ASSETS	\$547,449,519	\$367,295,107
	=====	=====
TOTAL LIABILITIES		
United States	\$137,931,564	\$130,484,540
Foreign	41,797,888	1,542,419
	-----	-----
TOTAL LIABILITIES	\$179,729,452	\$132,026,959
	=====	=====

The Company develops, manufactures and markets medical devices primarily for the treatment of patients suffering from respiratory disorders. Its products are used primarily in the home and in hospitals, as well as emergency medical settings and alternative care facilities. The Company sells and rents primarily to providers and distributors in the healthcare industry and closely monitors the extension of credit to both domestic and foreign customers, including obtaining and analyzing credit applications for all new accounts and maintaining an active program to contact customers promptly when invoices become past due. During the fiscal year ended June 30, 2002, one customer accounted for 10% of net sales. During the fiscal year ended June 30, 2001, that same customer accounted for 11% of net sales. No single customer accounted for 10% or more of net sales for the fiscal year ended June 30, 2000.

NOTE J -- RETIREMENT PLANS

The Company has a Retirement Savings Plan which is available to all U.S. employees. Employees may contribute up to 15% (to a defined maximum) of their compensation. Effective July 1, 2002, this contribution rate increases to up to 30% (to a defined maximum) of their compensation. The Company matches employee contributions (up to 3% of each employee's compensation) at a 100% rate and may

Edgar Filing: RESPIRONICS INC - Form 10-K

make discretionary contributions. Total Company contributions to these plans was \$1,774,000, \$1,307,000, and \$1,528,000, for the years ended June 30, 2002, 2001, and 2000, respectively. The Company's current benefit program does not provide any other postretirement benefits to employees.

NOTE K -- CONTINGENCIES

The Company is party to actions filed in a Federal District Court in January 1995 and June 1996 in which a competitor alleges that the Company's manufacture and sale in the United States of certain products infringes four of the competitor's patents. In its response to these actions, the Company has denied the allegations and has separately sought judgment that the claims under the patents are invalid or unenforceable and that the Company does not infringe upon the patents. The January 1995 and June 1996 actions have been consolidated, and discovery is ongoing. The Court has granted the Company's various motions for summary judgment and held that the Company does not infringe any of the competitor's four patents at issue. The competitor may seek an appeal of those

42

decisions. In any event, the Company intends to continue to pursue its claims that the competitor's patents are invalid or unenforceable.

The Company is, as a normal part of its business operations, a party to other legal proceedings in addition to those previously described by filings of the Company. Legal counsel has been retained for each proceeding and none of these proceedings is expected to have a material adverse impact on the Company's results of operations or financial condition.

In connection with customer leasing programs with independent leasing companies, the Company is contingently liable, in the event of a customer default, to the leasing companies within certain limits for unpaid installment receivables initiated by or transferred to the leasing companies. The transfer of certain of these installment receivables meets the criteria of Statement of Financial Accounting Standards No. 140, "Accounting for Transfers and Servicing of Financial Assets and Extinguishment of Liabilities," and therefore are not recorded on the Company's financial statements. The total exposure for unpaid installment receivables meeting these criteria and not recorded on the Company's financial statements was approximately \$18,428,000 and \$22,670,000 at June 30, 2002 and 2001, respectively. The transfer of the remainder of these installment receivables (consisting of installment receivables acquired as part of the Novamatrix acquisition) does not meet the criteria of this Standard and therefore must be recorded as collateralized borrowing arrangements. Accordingly, the Company has included \$11,826,000 of receivables sold with recourse as assets in prepaid expenses and other at June 30, 2002 and has recorded offsetting liabilities at that date in accrued expenses and other.

NOTE L -- RESTRUCTURING

In July 1999, the Company announced a major restructuring of its U.S. operations that included facility closings and downsizings, a management realignment, and a workforce reduction associated with those changes. The workforce reduction involved approximately 200 employees in areas of executive management, manufacturing, engineering, sales and marketing, administration, and service. The following table summarizes these restructuring charges and corresponding expenditures.

Reconciliation of Restructuring Reserves

Edgar Filing: RESPIRONICS INC - Form 10-K

	Employee Severance Costs	Asset Write-Downs	Lease Buyouts & Other Direct Expenses	Re
	-----	-----	-----	-----
Balance at July 1, 1999	\$ 0	\$ 0	\$ 0	\$
Restructuring charges (net)	6,300,000	8,900,000	14,000,000	
Cash expenditures	(3,100,000)	0	(12,900,000)	
Noncash expenditures	0	(1,700,000)	0	
	-----	-----	-----	-----
Balance at June 30, 2000	3,200,000	7,200,000	1,100,000	
Restructuring charges (net) (1)	(200,000)	1,000,000	0	
Cash expenditures	(1,500,000)	0	(900,000)	
Noncash expenditures	0	(2,500,000)	0	
	-----	-----	-----	-----
Balance at June 30, 2001	1,500,000	5,700,000	200,000	
Restructuring charges (net)	0	0	0	
Cash expenditures	(1,400,000)	0	(100,000)	
Noncash expenditures	0	(3,400,000)	0	
	-----	-----	-----	-----
Balance at June 30, 2002	\$ 100,000	\$ 2,300,000	\$ 100,000	\$
	=====	=====	=====	=====

(1) During the year ended June 30, 2001, the Company also recorded a gain of approximately \$2,000,000 on the sale of the Westminster, Colorado facility.

43

During fiscal year 2000, the Company incurred a total of \$29,200,000 in charges related to this restructuring. The primary components of these charges were severance and employment related costs (\$6,300,000), asset write-downs to reflect decisions made regarding product, facility, and systems rationalization (\$8,900,000), and lease buyouts related to facility rationalizations and other direct expenses of the restructuring (\$14,000,000). The non-cash expenditures presented as reductions of the asset write-down restructuring charge represent disposals of fully written-down assets, including rationalized inventories and impairments to long-lived assets held for disposal consisting of machinery, equipment, and computer software.

During fiscal year 2001, the Westminster, Colorado facility was sold as planned, and a gain of approximately \$2,000,000 was recorded on the sale. Also during fiscal year 2001, final restructuring expenses of \$800,000 were incurred, primarily for inventory write-offs of discontinued products.

Restructuring costs incurred but not yet paid have been credited to accrued expense and asset write-downs have been credited against the applicable asset accounts. Substantially all of the remaining restructuring accruals as of June 30, 2002 are expected to be paid out during fiscal year 2003.

NOTE M -- STOCK REPURCHASE

From August 1998 through September 1999, the Company's Board of Directors authorized several stock buybacks which represented authorization to purchase up to 4,000,000 shares of the Company's outstanding common stock. During fiscal year 2000, the Company repurchased, net of share usage, a total of 1,044,000

Edgar Filing: RESPIRONICS INC - Form 10-K

shares in open market transactions resulting in a net use of cash of \$9,201,000. No shares were repurchased during fiscal years 2001 or 2002. Including shares repurchased prior to fiscal year 2000, the Company has repurchased a total of 3,800,000 shares under this buyback program. Shares that are repurchased are added to treasury shares pending future use and reduce the number of shares outstanding used in calculating earnings per share.

NOTE N -- SUBSEQUENT EVENT

On August 19, 2002, the Company entered into a new Revolving Credit Agreement under which a total of \$150,000,000 is available, with similar terms and financial covenants to the Commercial Bank Credit Agreement (see Note D) and which expires in August 2005. The new Revolving Credit Agreement is also unsecured.

NOTE O - ACQUISITIONS

On April 12, 2002, the Company completed its previously announced acquisition of 100% of the outstanding common stock of Novamatrix Medical Systems Inc. ("Novamatrix"), a leading cardiorespiratory monitoring company that develops, manufactures, and markets proprietary state-of-the-art noninvasive monitors, sensors, and disposable accessories. The acquisition of Novamatrix was consummated pursuant to an Agreement and Plan of Merger dated as of December 17, 2001, pursuant to which Respiroics Holdings, Inc., a wholly owned subsidiary of the Company, was merged with and into Novamatrix (the "Merger"). The Company made this acquisition for various reasons, including: (a) the Novamatrix monitoring products complement the Company's therapeutic products used in the hospital environment, (b) the Novamatrix developmental care products complement the Company's infant management products and programs, (c) the Novamatrix cardiac output monitoring technologies have the potential to support the Company's initiatives in the congestive heart failure area, and with the acquisition, (d) the Company's "critical mass" of products, revenues, profits, and assets in these markets increased, and (e) the Company expects to reduce costs by integrating Novamatrix's business functions and processes. The results of operations of Novamatrix are included in the Company's consolidated income statement beginning on the acquisition date, April 12, 2002.

Upon consummation of the Merger, approximately 2,400,000 shares of the Company's common stock were issued to the former stockholders of Novamatrix, reflecting an exchange ratio of .2541 shares of the Company's common stock for each share of Novamatrix common stock. The exchange ratio was determined based on the weighted average selling price of \$31.48

44

for the Company's common stock for the 20 day trading period from March 11 through April 8, 2002. Novamatrix stockholders received the Company's stock in an amount equal to \$8.00 per Novamatrix share based upon the weighted average selling price. In addition, approximately 509,000 shares of the Company's common stock were reserved for issuance upon exercise of options and warrants issued in exchange for Novamatrix options and warrants that were not exercised prior to the consummation of the Merger. As of the close of trading on April 12, 2002, Novamatrix common stock ceased to be traded on the Nasdaq National Market.

The total value of the Company's shares issued and reserved for issuance in the transaction was approximately \$81.0 million based on the average fair market value of the Company's common stock during the three-day periods both before and after the first day the number of shares issued became fixed, plus the fair market value of the Company's common stock reserved for issuance. In addition, the Company incurred approximately \$3.4 million in transaction costs (consisting

Edgar Filing: RESPIRONICS INC - Form 10-K

primarily of investment banking and other professional fees and severance costs for certain Novamatrix employees), bringing the total acquisition cost to approximately \$84.4 million.

The following table summarizes the fair value of the assets acquired and liabilities assumed at the date of acquisition. The allocation of the purchase price may be subject to further refinement, primarily due to final determination of the recoverability and disposition of assets and liabilities based on events that existed at the acquisition date.

At April 12, 2002

Current assets, primarily	
consisting of accounts	
receivable and inventories	\$24,500,000
Property, plant and equipment	2,900,000
Intangible assets	17,700,000
Other noncurrent assets	1,400,000
Goodwill	47,500,000

Total assets acquired	\$94,000,000
Current liabilities, primarily	
consisting of accounts	
payable, accrued expenses,	
and current portion of	
debt	9,600,000

Net assets acquired	\$84,400,000
	=====

The amounts assigned to major classes of intangible assets are shown below:

Technology related assets,	
primarily patents	\$17,300,000
Non-compete agreements	400,000

Total intangible assets	\$17,700,000
	=====

The weighted average amortization period is approximately 15 years for the technology related assets, approximately three years for the non-compete agreements, and approximately 14 years in total.

Approximately \$3.1 million of goodwill is expected to be deductible for tax purposes.

Restructuring and integration costs related to the Novamatrix acquisition were incurred during fiscal year 2002. Severance costs of \$1,647,000 for the separation of

Edgar Filing: RESPIRONICS INC - Form 10-K

approximately 50 employees were incurred, of which \$1,336,000 was included in the acquisition costs shown above, and \$311,000 was recorded as integration and restructuring charges. All severance is expected to be paid out during fiscal year 2003. Integration and restructuring charges also included \$1,977,000 related to eliminating and centralizing certain duplicate back office functions. Cost of goods sold included \$1,653,000 related to reversing acquisition date inventory fair market value adjustments as inventory was sold subsequent to the acquisition.

In the fourth quarter of fiscal year 2002, the Company ceased work on an oxygen monitoring technology development project based in part on the results of a review of that technology by engineers from Novamatrix that was conducted after the acquisition. This decision resulted in an impairment charge totaling \$2,006,000 in the fourth quarter representing the write-off of intangible assets, inventory and fixed assets related to the project.

The pro forma summary below presents the Company's results of operations as if the acquisition had occurred at the beginning of the periods presented and does not purport to be indicative of what would have occurred had the acquisition been made as of those dates or of results which may occur in the future. These results do not include costs related to the acquisition or related restructuring and integration costs recorded in fiscal year 2002 or the positive impact of cost reductions and other synergies that are expected to be realized as a result of the acquisition.

	Year ended June 30	
	2002	2001
	----	----
Pro Forma Sales	\$531,606,000	\$477,120,000
Pro Forma Net Income	37,857,000	33,049,000
Pro Forma Earnings Per Share	1.12	0.99

Novamatrix had an April fiscal year-end, which differed from the Company's June year-end. In order to develop the fiscal year 2002 pro forma information, the Company's income statement for the year ended June 30, 2002 (which included Novamatrix's results of operations effective April 12, 2002) was combined with Novamatrix's unaudited income statement for the period July 1, 2001 through April 12, 2002. In order to develop the fiscal year 2001 pro forma information, the Company's income statement for the year ended June 30, 2001 was combined with Novamatrix's income statement for the year ended April 29, 2001. Earnings per share data are based on the Company's weighted average number of common shares outstanding plus the total number of the Company's common shares and equivalents delivered to Novamatrix stockholders as part of the acquisition.

In May 2002, the Company acquired a 60% controlling interest in Fuji, RC Co., Ltd., a leading provider of homecare and hospital products and services for respiratory-impaired patients in Japan, and entered into an agreement to purchase all of the remaining outstanding shares of Fuji in a multiple step acquisition by December 31, 2006. The base cash purchase price for all of the outstanding shares is approximately \$12 million with provisions for additional payment to one of the shareholders of Fuji to be made based on operating performance of Fuji over the next four years. These additional payments will be accrued as compensation over the four-year period as they are earned by the shareholder during his post-acquisition employment period. No amounts of the purchase price were assigned to goodwill or other intangible assets since the

Edgar Filing: RESPIRONICS INC - Form 10-K

initial purchase price equaled the fair market value of the net assets acquired.

46

NOTE P -- EARNINGS PER SHARE

The following table sets forth the computation of basic and diluted earnings per share:

	Year Ended June 30		
	2002 ----	2001 ----	2000 ----
Numerator:			
Net Income	\$38,416,868	\$33,571,284	\$ 5,752,284
Denominator:			
Denominator for basic earnings per share- Weighted average shares	31,079,282	29,962,366	29,660,366
Effect of Dilutive Securities- Stock Options and Warrants	929,077	923,677	343,389
	-----	-----	-----
Denominator for diluted earnings per share - Adjusted weighted average shares and assumed conversions	32,008,359	30,886,043	30,003,755
	=====	=====	=====
Basic Earnings Per Share	\$ 1.24	\$ 1.12	\$ 0.19
	=====	=====	=====
Diluted Earnings Per Share	\$ 1.20	\$ 1.09	\$ 0.19
	=====	=====	=====

NOTE Q -- QUARTERLY RESULTS OF OPERATIONS (UNAUDITED)

Following are the unaudited quarterly results of operations for the fiscal years ended June 30, 2002 and 2001:

	2002 ----			
	September 30 -----	Three Months Ended December 31 March 31		June 30 -----
Net Sales	\$107,409,000	\$117,384,000	\$126,708,000	\$143,418,000
Gross Profit	50,900,000	54,699,000	59,564,000	68,961,000
Integration, Restructuring and Impairment Charges	0	0	0	4,294,000

Edgar Filing: RESPIRONICS INC - Form 10-K

Net Income	8,102,000	9,957,000	11,316,000	9,042,000
Basic Earnings Per Share	0.27	0.33	0.37	0.28
Diluted Earnings Per Share	0.26	0.32	0.36	0.27

47

	2001			
	September 30	December 31	March 31	June 30
Net Sales	\$92,064,000	\$104,548,000	\$110,208,000	\$115,618,000
Gross Profit Including Restructuring Costs	43,402,000	49,436,000	50,787,000	54,726,000
Gross Profit Excluding Restructuring Costs	43,402,000	49,436,000	51,512,000	54,726,000
Restructuring Costs (Credits) - Net	0	0	(1,184,000)	0
Net Income	6,291,000	8,010,000	9,313,000	9,957,000
Basic Earnings Per Share	0.21	0.27	0.31	0.33
Diluted Earnings Per Share	0.21	0.26	0.30	0.32

Item 9. Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure.

None.

48

PART III

Items 10 through 13.

In accordance with the provisions of General Instruction G to Form 10-K, the information required by Item 10 (Directors and Executive Officers of the Registrant), Item 11 (Executive Compensation), Item 12 (Security Ownership of Certain Beneficial Owners and Management) and Item 13 (Certain Relationships and Related Transactions) is not set forth herein because prior to October 28, 2002 the Company will file with the Commission a definitive Proxy Statement which involves the election of Directors at its Annual Meeting of Shareholders to be held on November 18, 2002, which Proxy Statement will contain such information. The information required by Items 10, 11, 12 and 13 is incorporated herein by reference to such Proxy Statement.

PART IV

Item 14. Controls and Procedures

Not applicable.

Item 15. Exhibits, Financial Statement Schedules and Reports on Form 8-K.

The financial statements, financial statement schedules and exhibits listed below are filed as part of this Annual Report on Form 10-K.

(a) (1) Financial Statements:

The Consolidated Financial Statements of the Company and its subsidiaries, together with the report of Ernst & Young LLP dated July 23, 2002, except for Note N as to which the date is August 19, 2002, filed as part of this Annual Report on Form 10-K are listed in the index to Consolidated Financial Statements in Item 8.

(a) (2) Financial Statement Schedules:

	Page

Financial Statement Schedules:	
Valuation and Qualifying Accounts	50

FINANCIAL STATEMENT SCHEDULE
VALUATION AND QUALIFYING ACCOUNTS

RESPIRONICS, INC.

COL. A	COL. B	COL. C	COL. D	COL. E	
DESCRIPTION	Balance at Beginning of Period	Charged to Costs and Expenses	Charged to Other Accts- Describe	Deductions- Describe	Balance at End of Period
-----	-----	-----	-----	-----	-----
ADDITIONS					
Year ended June 30, 2002:					
Deducted from asset accounts:					
Allowance for doubtful accounts	\$16,457,000	\$3,275,000	\$	\$1,274,000 (a)	\$18,458,000
	=====	=====	=====	=====	=====
Year ended June 30, 2001:					
Deducted from asset accounts:					
Allowance for doubtful accounts	\$17,975,000	\$2,000,000	\$	\$3,518,000 (a)	\$16,457,000
	=====	=====	=====	=====	=====
Year ended June 30, 2000:					

Edgar Filing: RESPIRONICS INC - Form 10-K

Deducted from asset accounts:

Allowance for doubtful accounts	\$13,919,000	\$4,500,000	\$	\$ 444,000 (a)	\$17,975,000
	=====	=====	=====	=====	=====

(a) Write-off of uncollectible accounts.

All other Financial Statement Schedules have been omitted because they are not applicable to the Company.

50

(a) (3) Exhibits

Those exhibits listed on the exhibit index beginning on page 55 of this Form 10-K are filed herewith or incorporated by reference.

(b) Reports on Form 8-K:

Current Report on Form 8-K of Respironics, Inc. with a report date of April 26, 2002, announcing the completion of the acquisition of Novamatrix Medical Systems Inc. by the Company.

Current Report on Form 8-K of Respironics, Inc. with a report date of June 25, 2002, providing pro forma financial information relating to the acquisition of Novamatrix Medical Systems Inc. by the Company.

51

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

RESPIRONICS, INC.

By: /s/ James W. Liken

James W. Liken, President and
Chief Executive Officer

Date: September 30, 2002

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Company in the capacities indicated on September 30, 2002:

/s/ James W. Liken	/s/ James H. Hardie
-----	-----
James W. Liken (President and Chief Executive Officer	James H. Hardie (Director)

Edgar Filing: RESPIRONICS INC - Form 10-K

and Director)
(Principal Executive Officer)

/s/ Daniel J. Bevevino

/s/ Donald H. Jones

Daniel J. Bevevino
(Vice President and Chief Financial
Officer)
(Principal Accounting Officer)

Donald H. Jones
(Director)

/s/ Gerald E. McGinnis

/s/ Craig B. Reynolds

Gerald E. McGinnis
(Chairman of the
Board of Directors)

Craig B. Reynolds
(Director)

/s/ John C. Miles II

/s/ Joseph C. Lawyer

John C. Miles II
(Director)

Joseph C. Lawyer
(Director)

/s/ Douglas A. Cotter

/s/ J. Terry Dewberry

Douglas A. Cotter
(Director)

J. Terry Dewberry
(Director)

/s/ Sean McDonald

/s/ Candace L. Littell

Sean McDonald
(Director)

Candace L. Littell
(Director)

52

CERTIFICATIONS

I, James W. Liken, certify that:

1. I have reviewed this annual report on Form 10-K of Respironics, Inc.;
2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report; and
3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report.

Date: September 26, 2002

/s/ James W. Liken

Edgar Filing: RESPIRONICS INC - Form 10-K

James W. Liken
President and Chief Executive Officer

53

I, Daniel J. Bevevino, certify that:

1. I have reviewed this annual report on Form 10-K of Respironics, Inc.;
2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report; and
3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report.

Date: September 26, 2002

/s/ Daniel J. Bevevino

Daniel J. Bevevino
Vice President and Chief Financial Officer

54

EXHIBITS INDEX

Exhibit No. -----	Description and Method of Filing -----
3.1	Restated Certificate of Incorporation of the Company, filed as Exhibit 3.2 to Amendment No. 1 to Form S-1, Registration No. 33-20899.
3.2	Amendment to Restated Certificate of Incorporation of the Company, filed as Exhibit 3.2 to Form S-1, Registration No. 33-39938.
3.3	Amendment to Restated Certificate of Incorporation of the Company, filed as Exhibit 4.2 to Company's Registration Statement on Form S-8, Registration No. 33-36459.
3.4	Amendment to Restated Certificate of Incorporation of the Company, filed as Exhibit 4.2 to Company's Registration Statement on Form S-8, Registration No. 33-89308.
3.5	Amendment to Restated Certificate of Incorporation of the Company, filed as Exhibit 3.5 to Form 10-Q for fiscal quarter ended December 31, 1996.
3.6	By-Laws of the Company, filed as Exhibit 3.4 to Amendment No. 2 to Form S-1, Registration No. 33-20899.
3.7	Amendment to By-Laws of the Company on June 3, 1998, filed as

Edgar Filing: RESPIRONICS INC - Form 10-K

Exhibit 3.7 to Form 10-K for the fiscal year ended June 30, 1998.

- 3.8 Amendment to By-Laws of the Company on November 18, 1998, filed as Exhibit 3.8 to Form 10-Q for fiscal quarter ending December 31, 1998.
- 4.1 Loan Agreement dated November 1, 1989 between the Company and the Pennsylvania Economic Development Financing Authority, filed as Exhibit 4.1 to Annual Report on Form 10-K for Fiscal Year ending June 30, 1990.
- 4.2 Consent, Subordination, and Assumption Agreement dated April 20, 1990 between the Company and the Greater Murrysville Industrial Corporation, filed as Exhibit 4.2 to Annual Report on Form 10-K for Fiscal Year ending June 30, 1990.
- 4.3 Loan Agreement dated June 5, 1990 between the Company and the Redevelopment Authority of the County of Westmoreland, to be filed with the Commission upon request.
- 4.4 Consent, Subordination, and Assumption Agreement dated June 21, 1994 between the Company and the Redevelopment Authority of the County of Westmoreland, filed as Exhibit 4.4 to Annual Report on Form 10-K for Fiscal Year ending June 30, 1994.
- 4.5 Consent, Subordination, and Assumption Agreement dated February 22, 1995 between the Company and the Central Westmoreland Development Corporation, filed as Exhibit 4.5 to Annual Report on Form 10-K for Fiscal Year ending June 30, 1995.
- 4.6 Form of Rights Agreement between Respironics, Inc. and Chase Mellon Shareholder Services, L.L.C. filed as Exhibit 1 to Form 8A filed by the Company on June 28, 1996.
- 10.1 Amended and Restated Incentive Stock Option Plan of Respironics, Inc. and form of Stock Option Agreement used for Stock Options granted after December 31, 1987, filed as Exhibit 10.2 to Form S-1, Registration No. 33-20899.
- 10.2 Amended and Restated Employment Agreement between the Company and
55
Gerald E. McGinnis, filed as Exhibit 10.37 to Quarterly Report on Form 10-Q for fiscal quarter ended March 31, 1999.
- 10.3 Incentive Bonus Plan dated January 26, 1985, filed as Exhibit 10.16 to Form S-1, Registration No. 33-20899.
- 10.4 Consulting Agreement dated July 1, 1988 between the Company and Dr. Mark Sanders, filed as Exhibit 10.15 to Annual Report on Form 10-K for Fiscal Year ending June 30, 1989.
- 10.5 Distribution Agreement dated June 20, 1991 between the Company and Flexco Medical Instruments AG, filed as Exhibit 10.15 to Annual Report on Form 10-K for Fiscal Year ending June 30, 1991.
- 10.6 Employment Agreement dated and effective as of April 1, 1995 between the Company and Gerald E. McGinnis, filed as Exhibit 10.19 to Annual Report on Form 10-K for Fiscal Year ending June 30, 1995.

Edgar Filing: RESPIRONICS INC - Form 10-K

- 10.7 Employment Agreement dated and effective as of December 1, 1994 between the Company and Robert D. Crouch, filed as Exhibit 1 to Quarterly Report on Form 10-Q for the quarter ended December 31, 1994.
- 10.8 Separation Agreement and Complete Release dated September 2, 1999 between the Company and Dennis S. Meteny filed as Exhibit 10.38 to Quarterly Report on Form 10-Q for the quarter ended September 30, 1999.
- 10.9 1991 Non-Employee Directors' Stock Option Plan, filed as Exhibit A to 1991 Proxy Statement incorporated by reference into Annual Report on Form 10-K for Fiscal Year ending June 30, 1991.
- 10.10 1992 Stock Incentive Plan, filed as Exhibit A to 1992 Proxy Statement incorporated by reference into Annual Report on Form 10-K for Fiscal Year ending June 30, 1992.
- 10.11 Healthdyne Technologies, Inc. 1996 Stock Option Plan, filed as Exhibit 10.13 to Annual Report on Form 10-K for the fiscal year ended June 30, 1998.
- 10.12 Healthdyne Technologies, Inc. Stock Option Plan, filed as Exhibit 10.8 to the Healthdyne Technologies, Inc. Registration Statement on Form S-1, Registration No. 33-60706.
- 10.13 Healthdyne Technologies, Inc. Non-Employee Director Stock Option Plan, filed as Exhibit 10.9 to the Healthdyne Technologies, Inc. Registration Statement on Form S-1, Registration No. 33-60706.
- 10.14 Healthdyne Technologies, Inc. Stock Option Plan II, filed as an Exhibit to the Healthdyne Technologies, Inc. Annual Report on Form 10-K, for the year ended December 31, 1994.
- 10.15 Credit Agreement by and among RESPIRONICS, INC. as the Borrower, THE BANKS PARTY HERETO, as the Lenders hereunder, and PNC BANK, NATIONAL ASSOCIATION as the Issuing Bank, PNC BANK NATIONAL ASSOCIATION as the Administrative Agent and the Syndication Agent and BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION as the Documentation Agent, dated as of May 8, 1998, filed as Exhibit 10.1 to Quarterly Report on Form 10-Q for the quarter ended March 31, 1998.
- 10.16 Amended and Restated Employment Agreement dated September 1, 2000 between the Company and Steven P. Fulton, filed as Exhibit 10.16 to Annual Report on Form 10-K for the fiscal year ended June 30, 2001.
- 10.17 Employment Agreement dated October 21, 1996 between the Company and Geoffrey C. Waters, filed as Exhibit 10.16 to Annual Report on Form 10-K for the fiscal year ended June 30, 1997.
- 10.18 Amended and Restated Employment Agreement dated September 1, 2000 between the Company and Daniel J. Bevevino, filed as Exhibit 10.18 to Annual Report on Form 10-K for the fiscal year ended June 30, 2001.

Edgar Filing: RESPIRONICS INC - Form 10-K

- 10.19 Employment Agreement dated November 11, 1997 between the Company and Craig B. Reynolds, filed as Exhibit 10.22 to Annual Report on Form 10-K for the fiscal year ended June 30, 1998.
- 10.20 Supplemental Employment Agreement dated November 11, 1997 between the Company and Craig B. Reynolds, filed as Exhibit 10.23 to Annual Report on Form 10-K for the fiscal year ended June 30, 1998.
- 10.21 Amendment No. 1 to the Employment Agreements between the Company and Craig B. Reynolds dated February 11, 1998, filed as Exhibit 10.23 to Annual Report on Form 10-K for the fiscal year ended June 30, 2000.
- 10.22 Amendment to the Employment Agreements between the Company and Craig B. Reynolds dated June 29, 2000, filed as Exhibit 10.24 to Annual Report on Form 10-K for the fiscal year ended June 30, 2000.
- 10.23 Employment Agreement dated November 10, 1997 between the Company and John L. Miclot, filed as Exhibit 10.24 to Annual Report on Form 10-K for the fiscal year ended June 30, 1998.
- 10.24 Supplemental Employment Agreement dated November 10, 1997 between the Company and John L. Miclot, filed as Exhibit 10.25 to Annual Report on Form 10-K for the fiscal year ended June 30, 1998.
- 10.25 Tradename License Agreement dated as of April 21, 1995 by and between Healthdyne, Inc., now Matria Healthcare, Inc., and Healthdyne Technologies, Inc., now Respiroics Georgia, Inc., filed as Exhibit 10.23 to the Healthdyne Technologies, Inc. Form 8-K dated April 20, 1995.
- 10.26 Form of letter agreement by and among the Company, Healthdyne Technologies, Inc. and Matria Healthcare, Inc. confirming and amending Corporate Services Agreement and Tradename License Agreement between Healthdyne, Inc., now Matria Healthcare, Inc., and Healthdyne Technologies, Inc., now Respiroics Georgia, Inc., filed as Appendix D to Exhibit 10.17 to Quarterly Report on Form 10-Q (File No. 000-16723) dated November 14, 1997.
- 10.27 Amendment No. 1 to Healthdyne Technologies, Inc. Stock Option Plan, filed as Exhibit 10.40 to Healthdyne Technologies, Inc. Form 10-K/A for the year ended December 31, 1996.
- 10.28 Amendment No. 2 to Healthdyne Technologies, Inc. Stock Option Plan, filed as Exhibit 10.41 to Healthdyne Technologies, Inc. Form 10-K/A for the year ended December 31, 1996.
- 10.29 Lease Agreement, dated December 20, 1993, between Max L. Kuniansky, David L. Kuniansky, Amy Kuniansky Clark, Douglas S. Kuniansky and Healthdyne Technologies, Inc., now Respiroics Georgia, Inc., filed as an Exhibit to the Healthdyne Technologies, Inc. Annual Report on Form 10-K for the year ended December 31, 1993.
- 10.30 Employment Agreement dated November 10, 1997 between the Company and Robert Tucker, filed as Exhibit 10.35 to Annual Report on Form 10-K for the fiscal year ended June 30, 1998.
- 10.31 Supplemental Employment Agreement dated November 10, 1997 between the Company and Robert Tucker, filed as Exhibit 10.36 to Annual Report on Form 10-K for the fiscal year ended June 30, 1998.

Edgar Filing: RESPIRONICS INC - Form 10-K

- 10.32 Respironics, Inc. 1997 Non-Employee Directors' Fee Plan, filed as Exhibit 10.35 to Annual Report on Form 10-K for the fiscal year ended June 30, 1999.
- 10.33 Amendment No. 1 to Rights Agreement, dated as of June 28, 1996, filed as Exhibit 10.39 to Quarterly Report on Form 10-Q for the quarter ended September 30, 1999.
- 10.34 Employment Agreement, made as of October 1, 1999, by and between the Company and James W. Liken, filed as Exhibit 10.40 to Quarterly Report on Form 10-Q for the quarter ended March 31, 2000.
- 10.35 First Amendment to the Credit Agreement by and among RESPIRONICS, INC. as the Borrower, THE BANKS PARTY HERETO, as the Lenders hereunder, PNC BANK, NATIONAL ASSOCIATION as the Issuing bank, PNC BANK, NATIONAL ASSOCIATION as the Administrative Agent and the Syndication Agent and BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION as the Documentation Agent, dated as of August 19, 1998, filed as Exhibit 10.37 to Quarterly Report on Form 10-Q for the quarter ended December 31, 1998.
- 10.36 Second Amendment to the Credit Agreement by and among RESPIRONICS, INC. as the Borrower, THE BANKS PARTY HERETO, as the Lenders hereunder, PNC BANK, NATIONAL ASSOCIATION as the Issuing bank, PNC BANK, NATIONAL ASSOCIATION, as the Administrative Agent and the Syndication Agent and BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION as the Documentation Agent, dated as of December 9, 1998, filed as Exhibit 10.38 to Quarterly Report on Form 10-Q for the quarter ended December 31, 1998.
- 10.37 Amendment to the Employment Agreements between the Company and Craig B. Reynolds dated August 8, 2000, filed as Exhibit 10.43 to Quarterly Report on Form 10-Q for the quarter ended September 30, 2000.
- 10.38 Amendment to the Employment Agreements between the Company and Craig B. Reynolds dated August 16, 2000, filed as Exhibit 10.44 to Quarterly Report on Form 10-Q for the quarter ended September 30, 2000.
- 10.39 Third Amendment to the Credit Agreement by and among RESPIRONICS, INC. as the Borrower, THE BANKS PARTY HERETO, as the Lenders hereunder, PNC BANK, NATIONAL ASSOCIATION as the Issuing Bank, PNC BANK, NATIONAL ASSOCIATION, as the Administrative Agent, BANK of AMERICA, N.A. as the Syndication Agent and FIRST UNION NATIONAL BANK as the Documentation Agent, dated as of July 7, 2000, filed as Exhibit 10.45 to Quarterly Report on Form 10-Q for the quarter ended September 30, 2000.
- 10.40 Separation Agreement between the Company and Robert D. Crouch dated October 12, 2000, filed as Exhibit 10.46 to Quarterly Report on Form 10-Q for the quarter ended December 31, 2000.
- 10.41 2000 Stock Incentive Plan, filed as Exhibit A to 2000 Proxy Statement incorporated by reference into Annual Report on Form 10-K for the fiscal year ended June 30, 2000.
- 10.42 Respironics, Inc. Non-Employee Director Deferred Compensation Plan, filed as Exhibit 10.42 to this Annual Report on Form 10-K for the

Edgar Filing: RESPIRONICS INC - Form 10-K

fiscal year ended June 30, 2002.

- 21.1 List of Subsidiaries filed as Exhibit 21.1 to this Annual Report on Form 10-K.
- 23.1 Consent of Ernst & Young LLP, filed as Exhibit 23.1 to this Annual Report on Form 10-K.

58

- 99.1 Certification of James W. Liken, President and Chief Executive Officer
- 99.2 Certification of Daniel J. Bevevino, Vice President and Chief Financial Officer

59